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ABSTRACT OF DISSERTATION

SYNTHESIS AND CHARACTERIZATION OF POLY(SIMVASTATIN) INCORPORATED COPOLYMERS AND BLENDS FOR BONE REGENERATION
Common biodegradable polyesters such as poly(lactic acid) (PLA), poly(lacticco-glycolic acid) (PLGA) and poly(ε-caprolactone) (PCL) are used as drug delivery
vehicles for tissue regenerative applications. However, they are typically bioinert, with
drug loading limitations. Polymerizing the active agent or precursor into its respective
biodegradable polymer would control drug loading via molar ratios of drug to initiator
used for synthesis. Simvastatin was chosen due to its favorable anti-inflammatory,
angiogenic, and osteogenic properties. In addition, its lactone ring lends itself to ringopening polymerization and, consequently, the synthesis of poly(simvastatin) with
controlled simvastatin release.
Simvastatin was first polymerized with a 5kDa methyl-terminated poly(ethylene
glycol) (mPEG) initiator and catalyzed via stannous octoate to form poly(simvastatin)block-poly(ethylene glycol).

Molecular weights ranged from 9.5kDa, with a

polydispersity index (PDI) of 1.1 at 150 °C, to 75kDa with a PDI of 6.9 at 250 °C. Firstorder propagation rates were seen. Infrared spectroscopy showed carboxylic and methyl
ether stretches unique to simvastatin and mPEG in the copolymer, respectively. Slow
degradation was seen in neutral and alkaline conditions, with simvastatin, simvastatinincorporated macromolecules, and mPEG identified as degradation products.

Alternatively, triazabicyclodecene (TBD) was used to mediate simvastatin
polymerization. A lower temperature of 150°C led to successful polymerization using
5kDa mPEG, compared to at least 200 °C via stannous octoate. TBD was also successful
for reactions using 2 or 0.55kDa mPEG. The biodegradability of poly(simvastatin)block-poly(ethylene glycol) via TBD improved, losing twice more mass in phosphatebuffered saline, pH 7.4, than the copolymer synthesized via stannous octoate. Release
rates of three different copolymers synthesized demonstrated tunable simvastatin
release.
To further modulate degradation, poly(simvastatin)-block-poly(ethylene glycol)
was blended with 5, 2, or 0.55kDa mPEG-initiated PLA copolymers. The blends showed
a compressive elastic modulus ranging from 26 to 44MPa, within the magnitude of
trabecular bone (approximately 50MPa). Tunability in mass loss and release was also
seen due to varied ratios of incorporated PLA copolymers.
Lastly, copolymer degradation byproducts inhibited HMG-CoA reductase and
showed possible enhancement of osteoblastic activity in vitro. A pilot study using a
rodent calvarial onlay model showed tolerability of the polymers and potential for longterm evaluations of bioactivity. Poly(simvastatin) may be useful in regenerative
applications.
Keywords: poly(simvastatin), ring-opening polymerization, drug delivery, simvastatin,
regenerative applications
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Ch. 1 Introduction
The development of biodegradable polydrugs is an emerging and rapidly growing
area in drug delivery as they serve to significantly increase the weight percent of the
bioactive agent in the biomaterial, allowing the biomaterial to be comprised almost
entirely of the drug, while providing controlled release upon degradation. Polyactives,
termed by Uhrich’s group,1 encompass a broad range of therapeutic agents that are used
as monomers which are ultimately polymerized into their homopolymers or into a
polymer backbone. These systems have been investigated in response to drawbacks seen
in more common poly(lactic acid) (PLA)- and poly(lactic-co-glycolic acid) (PLGA)based drug eluting systems where the percentage of drug encapsulated or bound to the
polymer backbone can be limited. Different polyactives have been developed
incorporating well known therapeutic drugs into polymerized forms. However, little
investigation has been done that has taken advantage of lactonized structures found in
prodrugs or active agents to utilize ROP in effectively polymerizing their respective
resorbable polymers, specifically for tissue regenerative therapeutics.

Ahead, the

synthesis of a copolymerized form of simvastatin, a commercially available and
lactonized prodrug, and characterization of the degradable biomaterial is discussed for
bone regenerative applications.
Chapter 2 gives an overview of current treatments for bone repair and the
chemical and physical properties of common biodegradable polyesters utilized for bone
and soft tissue therapeutic applications.

The chapter further delves into different

polymerization mechanisms which occur during polyester synthesis, most often
1

determined by the catalyst used, and secondary monomeric or polymeric components
incorporated into the polyester by copolymerization or blending to help in tuning
degradation rates. The evolution of different methods used to incorporate bioactive
agents or drugs into the polymer matrix or backbone are also discussed, with a stronger
emphasis on osteogenic active agents. The discussion then leads into intended treatment
applications which include maxillofacial bone defects or fractures and periodontitis. The
chapter concludes with the specific aims of the project.
Chapter 3 addresses the different reaction conditions attempted to synthesize a
novel poly(simvastatin)-block–poly(ethylene glycol) copolymer using tin (II) ethylhexanoate (stannous octoate) as the catalyst. Quantitative analysis of copolymer growth
throughout the reactions, followed by copolymer degradation in different pH conditions,
was primarily discussed. Further qualitative characterization of the resulting copolymer
and degradation products via chromatography and spectroscopy methods was another
focus to demonstrate success in forming a polymeric biomaterial.
Chapter 4 alternatively elaborates on the synthesis of poly(simvastatin)-mPEG
diblock copolymer using triazabicyclodecene (TBD) as a catalyst, and touches on the
differing ring-opening polymerization mechanism it governs from stannous octoate. A
comparison between the two catalysts focuses on the reaction conditions, capability of
using different block components for copolymerization, and quality of the resulting
copolymer expressed by the biodegradability of the resulting copolymer.

The

comparison demonstrates the advantages of using TBD over stannous octoate in

2

synthesizing poly(simvastatin) and in synthesizing poly(simvastatin) copolymers with
different drug release rates.
Chapter 5 focuses on blending the most hydrophilic poly(simvastatin) copolymer
synthesized with different poly(lactide)-block-poly(ethylene glycol) copolymers at two
different weight ratios. Mass loss and resulting simvastatin amounts released in neutral
and enzymatic conditions were quantified to demonstrate the effect of blending on the
degradation rate of poly(simvastatin). Mechanical and crystalline properties were also
quantified to show the effect of blending on the physical properties of the resulting
blends.
Chapter 6 primarily looks at the bioactivity of the poly(simvastatin) copolymer
degradation products via

alkaline phosphatase expression and degree of myotube

formation in a muscle cell line. Biocompatibility of the copolymer was also observed in
a pilot in vivo study. Comparisons between the activities of degraded poly(simvastatin)
and poly(D,L-lactide) copolymers against the monomer and general controls demonstrates
the potential of tunable poly(simvastatin)-incorporated polymer biomaterials for bone
regeneration.
Overall, this dissertation focuses on the repurposing of simvastatin, well-known
for cholesterol-regulation, for regenerative applications by polymerizing the drug into a
biodegradable biomaterial for controlled simvastatin release. ROP was investigated as a
mechanism, novel in polymerizing simvastatin.

The continued investigation of

polyactives, including poly(simvastatin), can extend to other lactonized active agents

3

which advantageously use ROP as another method to create more effectively controlled
drug delivery systems for therapeutic applications.

Copyright © Theodora Atta Asafo-Adjei 2017
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Ch. 2 Background and Significance
2.1 Bone Grafts and Substitutes
The high incidence of bone defects results from a range of causes including
injury, infection, tumor resection, and abnormalities to bone and vascular diseases from
osteoporosis to various forms of necrosis.2-4 In many instances, these complications are
so extensive that natural bone repair becomes impaired and is no longer capable of
completely healing the wound. This hindered process leaves remaining fractures, voids,
and non-unions in need of external clinical intervention. Approximately 500,000 to
600,000 bone grafting procedures are performed annually in the US.5 Autografts, as well
as allografts, are used in approximately 2.2 million orthopaedic surgeries each year,
worldwide.6 Investigations that are being done to improve upon the disadvantages of
current treatment focus on multiple forms of biological and synthetic bone substitutes
which incorporate the desirable characteristics of synthetic polymers. Some of these
devices may administer drugs to enhance efficacy of the biomaterial. The development of
these materials aims towards developing the ideal material that eliminates the risk of
disease transmission and rejection, improves biocompatibility, and provides an easily
available, inexpensive, and abundance necessary for bone defect-related procedures.
2.1.1 Autologous and Allogenic Bone Grafts
Autografts are used as the primary bone graft of choice, or the “golden standard,”
because their use diminishes the possibility of rejection and infectious disease
transmission due to its harvest from the iliac or pelvic crest of the same patient in need of
5

the implant.7 They also possess four main properties needed for successful bone grafting:
osteoconduction, osteoinduction, osteogenesis and osteointegration.6 Osteoconduction is
the stimulation of bone tissue growth within the graft. Osteoinduction involves the
differentiation of mesenchymal stem cells into osteoblasts, leading to bone growth.
Osteogenesis stems from osteoprogenitor cells remaining in grafts that further proliferate
and differentiate into characteristic bone cells which adhere within the graft.
Osteointegration is the integrative bonding of the graft to surrounding bone tissue. Even
though the autograft seems ideal by possessing these primary characteristics, it requires
additional surgery to harvest the bone needed for the graft which increases the risk of
complication.3 In fact, 8 to 20% of complications arise from harvesting host bone.6
Allografts, harvested from cadavers or another host of the same species, are also used but
have an increased chance of rejection due to being foreign to the host along with
increased chances of transmitting infection or disease.3, 7, 8
2.1.2 Calcium-Based Substitutes
Ceramics used as synthetic bone substitutes are developed from calcium sulfate
(CaS), calcium phosphate (CaP), or bioactive glass derivatives.9,

10

Due to chemical

structure of CaP, which include hydroxyapatite (HA), ceramics being found in the
inorganic components of bone, these scaffolds are found to be favorably biocompatible,
and have been a focus alongside bone grafts to minimize the risk of infection otherwise
seen with bone grafts.11 Their biocompatibility is defined by bioactive ceramic surfaces
being able to form hydroxyl carbonate apatite (HCA) which bonds with surrounding
tissues at the implant interface.12 This characteristic enhances osteointegration, and its
6

porosity gives it osteoconductive properties as well, for bone tissue growth. However,
they are brittle leading to inadequate structural support.9 Also, while they are capable of
being resorbed, the resorption rate of some HA-incorporated implants can be extensively
slow.13

Shindo et al.

showed that approximately half the amount of their porous

hydroxyapatite cement implants were resorbed in bone within 9 and 18 months.14
Biodegradable polymers have instead been combined with these ceramics to improve
their mechanical and resorptive properties, and have also emerged on the forefront of
biomaterials being investigated for tissue repair and regeneration.
2.2 Common Biodegradable Polymers
Biodegradable polymers are increasingly being used for biomedical therapeutic
applications.

This is due to their desirable characteristics which include tunable

degradation, mechanical properties, and relative biocompatibility in the body. Their
ability to degrade allows for the avoidance of revision surgery to remove the implant, as
opposed to some fixation devices, after therapeutic treatment is done. This capability is
due to the hydrolytically labile bonds present within the polymer backbone of these
resorbable materials. Specific characteristics of each of the more common biodegradable
polymers make each very unique and the most favorable for their specific use.
2.2.1 Poly(lactic acid) (PLA)
Lactic acid, the monomer of PLA was first isolated in 1780 and commercialized
in 1880.15 PLA was then first developed into synthetic biodegradable sutures in 1969
before being considered for many other biomedical and drug delivery applications. 16
Good mechanical properties, thermoplasticity, and a thermal degradation temperature of
7

200 ˚C makes PLA a very suitable candidate for widescale processing (while within a
narrow temperature range of 185 to 190 ˚C).15

At desirably processable molecular

weights over 100 kDa, a high tensile strength and modulus around 61 MPa and 2.2 GPa,
respectively, are reached, which can be modified based on the ratio of lactide isomers
used in synthesis, making it adaptable for its intended application.17 The ratio of D to Llactide isomers also determines how amorphous or crystalline the polymer will be
allowing its degradation rate and glass transition temperature, normally around 55 ˚C, to
be slightly altered as well.15 Poly(D,L-lactic acid) is known to be the amorphous polymer
because of the randomized configuration of methyl groups in the polymer backbone,
creating more incoherent polymer matrix regions. Poly(L-lactic acid) has a uniform
backbone resulting in a rigid uniform matrix that water is less likely to penetrate. Upon
degradation, when PLA degrades into lactic acid, the simplest of its degradation products
via hydrolysis, it is recognized as a product developed in the body, and is later
metabolized into carbon dioxide and water via the Krebs cycle.18

PLA has been

copolymerized with poly(ethylene glycol) (PEG) and combined with hydroxyapatite to
develop different types of fabrications for bone regeneration.19,

20

It has also been

formulated into micro- and nanoparticles to release various classes of drugs for bone and
soft tissue healing, along with cancer therapies.
2.2.2 Poly(lactic-co-glycolic acid) (PLGA)
Like PLA, PLGA possesses many similar mechanical and degradation
characteristics making it amendable to processing for biomedical applications.

The

incorporation of glycolic acid and its properties into the polymer backbone does
8

introduce a broader range of adaptable changes in mechanical and degradation tunability.
With its lack of a methyl group, glycolic acid is more hydrophilic than lactic acid,
allowing PLGA to become a more hydrophilic and generally faster degrading polymer or
vice versa depending on the lactic acid to glycolic acid molar ratio in the polymer
backbone. However, the structural state of the polymer matrix plays the most influence
in its degradation at a 50:50 molar ratio which has been found to have the fastest
degradation rate compared to a greater incorporation of either monomer in the
backbone.21 This characteristic is most likely due to an increasing amorphous nature as
the incorporation of either lactide or glycolide monomer increases up to 50% as the
amorphous regions allows easier access of water into the polymer matrix allowing for
faster degradation.

Each of the homopolymers of the L-lactide stereo-isomer and

glycolide are known to be semi-crystalline, at 37 and 45-55%, respectively.22, 23 The Tg
range for PLGA can range from 44 to 55 ˚C, increasing in Tg as the lactide content and/or
MW increases.24, 25.

Like lactide, glycolide is also metabolized in the body or excreted

by the kidneys. Different localized formulations for bone, such as microparticle-sintered
scaffolds for growth plate regeneration and other micro- and nanoparticle systems have
been developed for drug delivery.26, 27
2.2.3 Poly(ε-caprolactone) (PCL)
PCL has previously been used in microelectronics, as an adhesive, and as an
ecological biodegradable plastic.28,

29

Originally viewed as a biodegradable ecological

plastic that degraded into non-toxic products via various microorganisms within the
natural environment, PCL soon began being used for medical applications due to its
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mechanical properties being similar to that of non-biodegradable polymers and for its
ability to degrade in the body.28 Due to its lack of functional groups attached to the 5carbon portion of the aliphatic chain, PCL is very hydrophobic and degrades very slow
compared to PLA and PLGA. Additionally, the lack of bulky side groups permits PCL to
form a semi-crystalline structure, with a -60 ˚C Tg, which becomes increasingly
crystalline as it degrades in its amorphous regions, allowing degradation to take up to
years via hydrolysis. Its degradation properties, in combination with faster degrading
polymers, has led to the synthesis of PCL block copolymers for sutures, such as
Monocryl®, and bioglass composites formulated into fixation screws, among other
devices for biomedical applications.23, 30 Compost microorganisms including Aspergillus
spp. and Penicillium funiculosum are able to enzymatically degrade PCL into succinic
acid, butyric acid, valeric acid, and hexanoic acid.28 However, within the physiological
environment of the body, studies have shown it incapable of degrading enzymatically. 31,
32

Thus, solely hydrolysis at its ester linkages allows the polymer to degrade into its

degradation products of 6-hydroxyhexanoic acid, its ε-caprolactone monomer, and the
cyclic dimer and trimer of the monomer.28 PCL has now been repeatedly utilized in bone
regeneration and other biomedical applications due to its degradation and mechanical
properties. PCL/hydroxyapatite composites and scaffolds have been developed as a
result.33, 34
2.2.4 Poly(anhydrides)
The unique chemistry of poly(anhydrides) sets them apart from other
biodegradable polymers, allowing multiple subclasses of the polymer to be synthesized
10

which can ultimately degrade by surface erosion, instead of the bulk erosion experienced
by polyesters like PLA, PLGA, and PCL. Aliphatic poly(anhydrides) were originally
synthesized and extruded into fibers in 1932 by Carothers and Hill35 and was eventually
used in textiles, but was later discarded from the industry because of its hydrolytic
instability.

Langer and his group later took advantage of the polymer’s degrading

properties for therapeutic controlled drug delivery in 1980.36 Since then, the polymer’s
desirable bioerodible qualities have been used in more localized drug release therapies for
malignant tumors, thrombosis and restenosis, infection, but moreso for glaucoma, retinal,
and neurological disorders.37, 38 For example, poly(anhydrides) have been fashioned into
disks and injectable microparticles releasing 5-fluorouridine to extend the reduction of
intraocular pressure after glaucoma filtration surgery.39,

40

An FDA approved

poly(anhydride), known as Gliadel®, has been formulated into wafers releasing
carmustin, a chemotherapeutic, for treating brain tumors.37 Cylinders of the polymer have
also been made to locally deliver anesthetic to the sciatic nerve for pain.41 Bioerodible
poly(anhydrides) in medicine are generally synthesized with diacids resulting in the labile
anhydride group embedded within the polymer chain capable of degrading within weeks.
In non-degradable poly(anhydrides), the anhydride is instead a side group. They are
crystalline, opaque polymers with melting points between 50 ˚C and 120 ˚C dependent on
the manipulation of their polymer chemistry.

Altering their chemistry has led to the

development of poly(ester-anhydrides)42, aromatic, aliphatic-aromatic, unsaturated,
branched, and crosslinked poly(anhydrides) among many others, for different
applications.37
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2.3 Polymer Synthesis
Different types of polyester synthesis are utilized to achieve a desired polymeric
architecture. The mechanisms by which these architectures are constructed may be
dictated by the catalyst and is confined to the chemistry of the monomers and initiators
being used. A combination of these different forms of polymerization can be used
sequentially in order to develop the desired biomaterial.
2.3.1 Radical Polymerization
In radical polymerization, a free radical, or possible cation or anion, acts as the
initiator by cleaving a pi-bond within the monomer and forming a new reactive species
that continues chain propagation, repeating the process.

One form of radical

polymerization is photopolymerization.43 It is generally used to achieve a desired gelation
or crosslinking of polymer chains to form hydrogels in various drug delivery applications
and to cure non-amalgam restorative dental applications.44-46 The degree of crosslinking
directly relates to the amount of swelling the hydrogel is capable of undergoing in order
to release entrapped drug. The method and reaction of photopolymerization is usually
very simple and quick, requiring an accessible ultraviolet (UV) light source and
photoinitiator within the macromer acrylate mixture. Afterwards, the gel is washed in an
aqueous medium to remove any residual macromer and initiator. UV light bombards light
susceptible photoinitiators, cleaving C-C, C-Cl, C-O, or C-S bonds in double bonds to
form radicals and initiate propagation. The UV light may also promote hydrogen atom
transfer from a H donor to the photoinitiator forming hydrogen and ketal radicals for
polymerization, also known as hydrogen abstraction. Sawhney et al. developed acrylate12

terminated PEG-block-oligo(lactide) and PEG-block-oligo(glycolide) macromers which
were made into crosslinkable gels via photopolymerization.47
2.3.2 Direct Condensation of Biodegradable Polymers
Poly(α-hydroxy acids) like PLA and PLGA can be synthesized by direct
condensation when the simplest reactant units of the polymer, lactic acid and glycolic
acid, are chosen for synthesis. In this form of step polymerization, the hydroxyl and
carboxylic terminal end-groups of these monomers allows them to undergo an
intermolecular reaction with like monomers. This results in the formation of dimers,
trimers, and oligomers of varying lengths, along with the loss of a water molecule driven
by the high temperature conditions of the reaction. At times a coupling agent, such as
zinc compounds, carbodiimide or a phosgene compound,48 is used to enhance the
efficiency of polymerization, but otherwise the aid of a catalyst is not needed.49 While
the methodology for direct condensation is fairly simple, the process generally forms
oligomeric low molecular weight (MW) polymer chains. The mechanically unstable and
quickly degrading formulations these polymers would make are not ideal for biomedical
therapeutics. The increasing difficulty of distilled water removal with increased melt
viscosity, followed by the equilibrium between water and acid reactants limit the
progression of polymer chain growth.17
In other instances, the monomers can be bifunctional, such as diols or diacids.
This characteristic only allows one type of monomer to react with a different monomer
type within the mixture.50 However, some exceptions to this to this concept have been

13

reported by Uhrich et al. which includes the melt condensation of dicarboxylic acid
monomers to develop salicylic acid-based poly(ester-anhydrides).42, 51
2.2.3 Ring-Opening Polymerization of Poly(α-hydroxyacids) or Poly(lactones)
Ring-opening polymerization (ROP) requires the use of cyclic monomers, such as
the lactone or cyclic dimer structures of lactic and glycolic acid, otherwise known as
lactide and glycolide. An initiator and catalyst are usually necessary for the reaction to
begin and to further mediate the type of ROP mechanism that occurs.

The main

mechanisms of ROP that exist are coordination-insertion or pseudo-anionic, anionic,
cationic and monomer activated ROP.29 Coordination-insertion involves an alkoxide
nucleophilic initiator which coordinates with the lactone ring moiety of the monomer,
then inserts the monomer into its metal-oxygen bond while cleaving the ring open at the
acyl-oxygen bond to propagate the polymer chain. The metal remains at the end of the
chain to continue propagation, otherwise known as a living polymerization.29, 52 It is the
most common form with an array of metal and metal alkoxide catalysts that mediate this
mechanism, which include tin (II) octoate, tin triflate, and lanthanum, aluminum, and
yittrium isopropoxide.29 Anionic ROP also has a nucleophilic initiator which acts on the
carbon atom of the carbonyl group of the lactone, which in turn drives open the ring at
the acyl-oxygen bond. Catalysts that mediate anionic ROP mechanisms include small
oxides like potassium methoxide,53 to organocatalysts such as 1,3-dimesitylimidazol-2ylidene (IMes), diazabicycloundecene (DBU), and triazabicyclodecene (TBD).54,

55

In

cationic ROP, the oxygen in the carbonyl group of the lactone acts on the cationic
catalyst to initiate ring opening of the lactone. Various acid cosystems can be used as the
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catalyst for this mechanism, such as hydrochloric acid in diethyl ether.56 Lastly, the
monomer can act as an activated catalyst that continuously adds to the end of the polymer
chain. In all instances, ROP reactions lead to the synthesis of high MW polymers with
relatively low polydispersity and is considered one of the more preferred methods of
polyester synthesis.
2.4 Tuning Polymer Degradation
The mechanisms and properties influencing polymer are invaluable to understand
in their development for specific drug delivery applications. Depending on whether the
therapy is intended for bone tissue healing, which may require longer times of treatment,
to fibrotic tissue prevention, requiring relatively shorter treatment periods, the rate of
degradation will have to accommodate the recovery time of the specific type of injured
tissue in question.
2.4.1 Polymer Architecture
The architecture of the polymer chain may influence how the resulting polymeric
biomaterial degrades. Polyesters, such as PLA, PLGA, and PCL undergo bulk erosion
which creates an increasingly acidic environment within the bulk as more ester bonds
cleave within polymer chains, exposing carboxylic end groups. An accelerated form of
degradation results from this occurrence, known as autocatalysis, which is represented by
a first-order rate with respect to the copolymer, water, and autocatalytic acid products.57,
58

Polymers like poly(anhydrides) generally undergo surface erosion due to a

combination of high hydrophobicity and highly water-labile bonds, impeding water
penetration into the polymer matrix while easily cleaving linkages on the surface of the
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bulk sample. This process is represented by zero-order degradation kinetics and near
zero-order drug release from the matrix.1, 59 However, when the linear chains of some of
these polymers have been chemically manipulated to incorporate branched members of
the polymer chain or branched linkers, the rate of polymer degradation may be affected.
An increased degradation rate was seen in star-branched PLGA and PLA copolymers
with multi-arm poly(ethylene glycol) (PEG) initiators compared to their linear block
copolymer counterparts due to the extended retention of multifunctional PEG in the
microparticle polymer matrix.60 Biphasic forms of degradation, presented in terms of
decreasing molecular weight, was discovered of hyperbranched poly(silyl-esters)
compared to its linear polymer counterpart, showing a more linear decrease in MW with
time.61 Many other graft, comb, and dendritic types of branched polymers have been
explored as potential biomaterials for drug delivery due to some of their unique
degradation properties. 62, 63
2.4.2 Poly(ethylene glycol) (PEG) Conjugation and Blending
PEG is a hydrophilic polymer synthesized from ethylene oxide via ring opening
polymerization.64

It has repeatedly been coated on, copolymerized and covalently

bonded with aliphatic polyesters that have been formulated into micro- and nanoparticle
systems for targeted drug delivery.65 PEG’s common use stems from its protective
qualities that prolong circulation throughout the body, extending the drug release and
therapeutic treatment of these particles, and ultimately increasing their biocompatibility.
The terminal-end hydroxyl groups and ether linkages throughout the backbone solubilize
PEG in water. Its hydrophilic nature combined with an absence of functional groups
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allows for PEG incorporated surfaces to become more nonionic, minimizing protein
adsorption, and further masking the immunogenicity of the system and its bioactive
agents, systemically and locally.65-67 More specifically, the polymer and agents are
shielded from premature and proteolytic degradation from phagocytic cells before
reaching targeted tumors or the blood-brain barrier for treatment.68
While PEGs are useful for creating relatively bioinert biomaterials, they also
serve as avenues to tune the degradation rate and crystallinity of aliphatic polyester-based
materials as a plasticizer, blend, or via copolymerization. Hydrophobic polymers like
PLA, PLGA, and PCL which can be slow to degrade, can be made more hydrophilic via
copolymerization, enhancing water uptake of the polymer. As the MW of PEG increases,
the more hydrophilic the copolymer becomes. While the Tg of PEG remains at -60 ˚C as
MW increases,69 crystallinity increases up to a point which may contribute to better
toughness of the resulting polymeric biomaterial. Li et al. found that at 10 wt% of PEG in
PLA/PEG blends, crystallinity and impact strength decreased as PEG MW increased up
to 6000 Da. Crystallinity and impact strength increased as PEG MW increased from 6000
Da to 20 kDa.70 However, as seen with Li et al.’s study, the weight percent and MW of
PEG chosen can also impede specific mechanical properties. Sungsanit et al. found that
blending PLA with 1000 Da PEG increased impact strength, crystallinity, and elongationat-break and decreased the modulus and tensile strength with increasing PEG wt%.71
2.5 Drug Encapsulation in Polymeric Systems
Encapsulating drugs or bioactive molecules was first explored in the early 1930s
as a method of protection before the technique was adapted to drug delivery concepts
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utilizing biodegradable polyesters (i.e. PLA and PLGA) in the 1970s, and has since
become the most common and well-known method for drug incorporation.72 The most
common and simplistic forms of drug encapsulation in micro- and nanoparticle systems
include oil-water (o/w) and water-oil-water (w/o/w) emulsions which entrap the drug to
be released. Bioactive agents significantly soluble in organic solvents undergo the o/w
technique where the polymer and drug are dissolved in an organic solvent, such as
dichloromethane or acetone, before adding to an aqueous solution with an incorporated
surfactant, such as poly(vinyl alcohol) or Pluronic F-68, to obtain polymeric spherical
particles with entrapped drug after the solvent is evaporated. For agents more soluble in
water, an additional water phase is added (i.e, w/o/w). Parameters that affect the rate of
release include polymer composition, polymer molecular weight, polymer-to-drug
interactions and ratios. Proteins are known to adsorb onto PLGA matrices which can
cause slow dissolution rates or lead to incomplete cumulative release in drug delivery
systems.73
Lax or vague consideration of the volume ratios of dispersed to continuous
phases, the organic solvents and aqueous solutions chosen in relation to drug solubility,
or the partitioning characteristics of the drug between organic and aqueous phases, may
result in low encapsulation efficiencies.

For example, using an o/w method for

encapsulating a hydrophobic drug like hydrocortisone, also partially soluble in aqueous
phases, would lead to expected low drug loading. As a result, emulsion techniques such
as oil-in-oil (o/o) and solid–in oil-in water (s/o/w) exist, along with other method
variations.72
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In fluorescein isothiocyanate (FITC)-dextran and FITC-immunoglobulin G (IgG) loaded
PLGA/PEG blended microparticles, developed by Cleek et al., the percent encapsulation
efficiencies increased from 67 to 77% as the PEG content decreased with dextran
incorporation, and increased from 85 to 92% as the PEG content also increased with
IgG.74 These percentages lead to total drug loading weight percents ranging from 0.67 to
0.92 which are close to the theoretical loading of 1 wt%. Weight percents reported in the
study represent a normal range for some polymeric microparticle systems, and while
others have attained higher loading percentages, the formulation exposes a limitation or
predictable cap to the drug payload, despite their effectiveness. Polymeric microparticle
systems in the market include Decapeptyl® Depot, Vivitrol®, and Lupron Depot®
formulated using coacervation (water-in-oil), o/w, and w/o/w methods, respectively, to
entrap peptides and proteins for cancer, disease, and substance dependency therapies.72
2.6 Polymer-Drug Conjugations
Most of the previously described polymeric systems have bioactive agents
dispersed throughout the polymer matrix, which may have limitations in drug loading
capacity or premature burst drug release due to the structure of the polymer matrix. To
better control release, various forms of polymer-drug conjugations have been
formulated.1 Ringsdorf first introduced the concept of polymeric drugs in 1975 by
proposing a model which included a polymer backbone, targeting moiety, and linker
molecule from the polymer backbone which covalently linked to the bioactive agent.75, 76
Since then, many different types of non-degradable polymeric drug formulations have
been synthesized, utilizing PEG, poly(lysine), poly(glutamic acid), poly(phosphazene),
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and crosslinked hydroxypropyl methacrylate (HPMA) polymers, bound to antioxidant,
anticancer, and anti-inflammatory drugs such as peroxidase, doxorubicin, and
methotrexate, respectively.66, 76 A couple of PEG-drug conjugated systems in the market
are Oncaspar®, and Macugen® for leukemia and macular degeneration, respectively.
The field has continued to grow with the development of biodegradable polymeric
active systems. Systems where the drug still remains as a side group, but bound to a
hydrolytically labile polymer backbone, include the synthesis of linear PEG, sebacic acid,
and glycerol comprised polyesters with ketoprofen side groups, developed by Wang et.
al.1 Novel polyesters with ibuprofen and naproxen side groups have also been
synthesized by Uhrich’s group.1

Antioxidant and anti-microbial phenols such as

curcumin and quercetin have also served as active pendant groups conjugated into
poly(β-amino ester) backbones.77, 78 Biodegradable polydrugs or polyactives have also
been developed where the bioactive structure is either chemically incorporated into the
polymer backbone or serves as the monomer to its respective homopolymer. Different
examples of this class of polyactives include the novel synthesis of salicylic-based
poly(ester-anhydride)s, poly(trolox-ester) and poly(peroxalate-ester) polymers, along
with polymers comprised of antibiotic, analgesic and antiseptic monomers for bone, antiinflammatory, and antioxidant therapeutics.1

Before polymerization, the bioactive

molecules are most likely activated or further synthesized into a diol or diacid monomer
precursor, either by reacting with a cyclic anhydride, acyl chloride, or other linker
component, before typically undergoing a solution polymerization via a step mechanism
using a coupling agent. The advantage of polyactives over more common encapsulation
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methods is that the drug weight percent within the polymer system is significantly
increased while controlled release rates are still maintained.
2.7 Osteogenic Bioactive Agents
Different bioactive factors are commonly incorporated into biodegradable
polymeric systems to enhance bioactivity, more specifically, osteogenic and
osteoinductive agents for bone. Osteogenic agents include families of growth factors such
as insulin-like growth factor (IGF-1) and transforming growth factor (TGF) β, which
includes bone morphogenetic proteins (BMPs) [4-7]. Statins are also recognized for their
osteogenic properties which have been taken advantage of in drug delivery systems for
bone regenerative applications.79-84
2.7.1 Bone Morphogenetic Proteins (BMP)
BMPs are a class of osteoinductive proteins that belong to the TGF-β superfamily.
More specifically, they are known as differentiation factors since they induce
vascularization, proliferation, and maturing of mesenchymal cells into bone and cartilage
cells.85 They differentiate cells by binding to surface cell receptors which initiate the
Smad transduction pathway, and causes the expression of an osteoblastic phenotype.
BMPs initiate osteoblastic phenotypic expression in cells not related to bone, such as fat
and muscle cells.86 In the1970s, Urist found that these BMP amino acid sequences
responsible for osteoinductive activity could be isolated and extracted from the mineral
component of bone. Since then, more than 20 different types of proteins related to BMPs
have been discovered.87 BMP-2 and BMP-7 have been FDA approved and extensively
investigated in literature for bone regeneration, since both have similar sequences and
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mechanistic pathways, activity in vivo, and induce osteoinduction at lower concentrations
compared to other BMPs.85, 87 Among other BMP-2-incorporated polymer systems,88, 89
Laurencin et al. also constructed a system using PLGA/hydroxyapatite composites with
seeded BMP-2 expressed cells.90 Alveolar and mandibular bone formation was also seen
in surgically made defects using collagenous and demineralized bone matrices with BMP
-2.87

Currently, BMPs are produced by either transfecting BMP DNA coding into

mammalian cells which express and amplify the sequence and is later removed from the
cells (recombinant BMP) or by purifying the protein from the bone extract using
chromatography.85 However, reproducing the protein has very high costs due to low
recovered yields from its expression in mammalian systems.91, 92 Ectopic bone formation
leading to a delayed onset of nerve compression has also been seen with its use in lumbar
spinal fusion treatments, which adds to its disadvantages in bone repairing applications.93
2.7.2 Statins in Bone Repair
Statins are most well known as lipid-regulating agents by inhibiting 3-hydroxy-3methyl-glutaryl coenzyme A (HMG CoA) reductase in the mevalonate pathway.94 The
inhibition of the committed step, occurring early in the pathway, subsequently inhibits
geranyl and farnesyl pyrophosphate isoprenoid precursors, which lead to the prenylation
of Ras and Rho proteins involved in multiple cell signaling pathways influencing cell
proliferation and differentiation.94,

95

As a result, statins are also attributed pleiotropic

properties which can be utilized for tissue repair. Agents within the statin family include
lovastatin, simvastatin, mevastatin and pravastatin, directly and indirectly derived from
the fungus Aspergillus terreus, along with synthetic statins: atorvastatin, cerivastatin,
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fluvastatin, pitavastatin and rosuvastatin.96

Their slight differences in structural

chemistry allow for some, mainly pravastatin and rosuvastatin, to be hydrophilic
molecules, while the others remain lipophilic, more capable of crossing cellular
membranes by passive diffusion and being metabolized hepatically by P450 cytochrome
enzymes, excluding pitavastatin.96 Expressed activity levels also differ between statins.
Mundy et al. tested lovastatin, among many other natural products, with an assay
measuring the BMP-2 expression, a strong promoter of osteoblastic proliferation and
differentiation.97 The group found the statin to be the only product from their collection
to upregulate BMP-2, and subsequently tested other statins for comparable osteogenic
activity. Simvastatin, at an oral 5 to 50 mg/kg/day dose, caused a 25 to 94% increase in
trabecular bone volume in ovariectomized rats after 35 d. Since this investigation,
simvastatin has been extensively studied for bone formation and has been utilized in
many polymeric drug delivery devices for bone repair in maxillofacial and periodontal
therapeutics. For example, alveolar bone growth was seen in mandibular tooth sockets
after the implantation of a simvastatin-loaded PLA-PGA copolymer system.95 Yazawa et
al. also found that simvastatin enhanced cell proliferation and alkaline phosphatase
activity in periodontal ligament cells.98 However, statins have been seen to induce
myositis, rhabdomyolysis, and hepatotoxicity at high doses,99 which is why local instead
of systemic delivery may be a better avenue for treating bone.
2.8 Significance
A reported 66-87% of bone fractures seen in trauma centers in the US and Puerto
Rico are head injury related.100 Other cranio-maxillofacial bone defects include cleft
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palate, and alveolar to calvarial deformations left from trauma, disease, and genetic
events requiring complex treatment. The World Health Organization reported 1/2000
births with cleft palate in the world’s western populations and 1/1600 newborns affected
with other craniofacial anomalies.2 In adults, periodontitis is a common disease causing
bone loss in the alveolar region from severe stages of chronic gingival infection. The
disease is prevalent in 42.7% of adults in the US and 70.1% of adults 65 yr and older.101
Bone defects caused by these factors often lead to repeated surgeries involving graft
implantation. Autologous bone grafting has continued to be the standard for treatment
for osseous defects but has also contributed to post-operative complications.
Bioresorbable polymeric biomaterials have been included in a host of bone
substitutes investigated to improve upon the drawbacks of current treatment. They serve
to degrade and release bioactive agents to promote bone growth, while also preventing
the need for revision surgery. However, some of these polymeric biomaterials come with
their own disadvantages, such as a limited loading capacity of active agents which may
not be sufficient for sustained delivery or localized tissue repair. Synthesizing a
degradable osteogenic polymerized prodrug would serve to combat these issues for bone
tissue regeneration. Simvastatin was chosen for investigation due to ample amounts of
existing literature investigating its osteogenic properties, its chemical structure being
amendable to polymerization, multiple properties benefiting the healing and growth of
supporting vascular tissue, relatively inexpensive cost, and ease in accessibility.
Synthesizing poly(simvastatin)-block-poly(ethylene glycol) would prolong simvastatin
release while increasing the simvastatin loading capacity to weight percentages not
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characteristically seen in current polymeric systems, making the biomaterial more
efficient for localized treatment.
2.9 Specific Aims
Aim 1: Synthesize and characterize a degradable mPEG-poly(simvastatin) diblock
copolymer.

The molecular structure of simvastatin possesses a lactone moiety

amendable to ring opening polymerization (ROP). Reaction conditions were determined
for polymerizing simvastatin.

The synthesized product was analyzed using various

separation and spectroscopy techniques to determine bond formation, composition and
quality. The copolymer was then degraded to characterize its degradation products.
Aim 2: Assess the tunability of the mechanical and degradation properties of
poly(simvastatin)-block-poly(ethylene

glycol)

and

poly(simvastatin)-based

biomaterials. Poly(ethylene glycol)s of different MWs can alter the rate of water uptake,
and thus degradation, of the resulting copolymer when copolymerized with a more
hydrophobic polymeric block. Blending poly(simvastatin)-block-poly(ethylene glycol)
with another aliphatic polyester with different degrading and physical properties will
influence the degradation and simvastatin release rate of the poly(simvastatin) component
of the blend, along with altering mechanical properties. PLA copolymers initiated with
three different MW PEGs were blended with poly(simvastatin)-block-poly(ethylene
glycol) (5 kDa mPEG) at 2 different weight percentages to examine effects on
mechanical strength and degradation.
Aim 3. Test the bioactivity of its degradation products biochemically and in vitro
and in vivo. Degradation products of the implant will remain active and furthermore
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promote osteogenic effects on surrounding tissue to restore natural bone. Cytotoxicity of
poly(simvastatin)-block-poly(ethylene glycol) and its degradation products were
investigated. The copolymer and degradation products were then tested biochemically
and in vitro for osteogenic activity. Biocompatibility was also observed in vivo.
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Ch. 3 Synthesis and Characterization of a Poly(ethylene
glycol)- Poly(simvastatin) Diblock Copolymer
This chapter was reproduced from a published manuscript, “Asafo-Adjei T.A., T.D.
Dziubla, D.A. Puleo, Synthesis and characterization of a poly (ethylene glycol)–poly
(simvastatin) diblock copolymer. RSC Advances. 2014;4(102):58287-98.”

3.1 Introduction
The use of biodegradable polymers in therapeutic applications has grown due to
their favorable characteristics, which include biocompatibility, tailorable degradation,
and the ability for some polymer degradation products to be metabolized.23,

102

Poly(glycolic acid) (PGA), poly(lactic acid) (PLA), and poly(lactic-co-glycolic acid)
(PLGA) are among the earliest biodegradable polyesters to be investigated. Unlike the
degradation products of some polyesters, such as poly(ε-caprolactone), glycolic and lactic
acid are fully metabolized in the body.103 Commercial products based on these polymers
include PGA/PLA sutures, approved by the FDA in 1971, to PLGA-collagen and PLA
meshes and devices on the market for clinical regenerative treatments.104

These

degradable biomaterials can also encapsulate active agents within their matrices or in
reservoirs, but polymers have also carried covalently conjugated drugs.105 Polymer-drug
conjugates have been a prevalent method of drug delivery since their conceptual
development in 1975 to many different conjugates currently used.106, 107 These systems
have used synthetic polymers, such as poly(lysine), poly(glutamic acid), and
poly(phosphazene), to bind anti-cancer and anti-inflammatory drugs along their backbone
via cleavable hydrazine bond linkers.108, 109
While several characteristics of polyesters are advantageous, promoting their
recurrent use in drug delivery, these biomaterials can have a limited capacity to entrap
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drug.110, 111 Also, if structural or mechanical loading-induced defects exist in coated or
drug repository devices, dose-dumping could lead to concentrations high enough for toxic
effects to occur.112-114 Drug conjugation to the polymer backbone can prevent this issue,
and it can preserve activity by shielding drugs from degradation as well as prolong drug
circulation.107

However, this system also has the disadvantage of limited linkages

available for drug loading.109
Incorporation of drug into the polymeric backbone, such as the degradable
aspirin-derivatized poly(anhydride ester)115 and poly(trolox ester) polymers116 developed
for anti-inflammatory and antioxidant therapeutic applications, respectively, circumvents
limited drug loading. In these polymers, the weight percentage of drug is increased to
nearly 100% as a result of these active molecules essentially being linked to each other to
form a macromolecule. The step growth and esterification polymerization mechanisms
used to synthesize polydrugs such as the ones mentioned can require multiple reaction
steps, however.

Little literature exists on utilizing the molecular chemistry of a

therapeutic agent to create the backbone of its homopolymer or copolymer via ringopening polymerization (ROP), such as the polymerization of lactonized ricinoleic
acid.117
ROP has been utilized to polymerize lactones, among many types of cyclic
monomers, into their respective polymers. Lactide and glycolide are examples of lactone
monomers used to synthesize PLA, PGA, and PLGA via ROP, which can be initiated by
metal or organic catalysts to obtain high molecular weight macromolecules.118 Potential
drawbacks that exist in the mechanism include competing depolymerization reactions and
other side reactions that can influence the yield and quality of the resulting polymer.119
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However, ROP is versatile in using a range of hydroxyl-containing macromolecules and
alcohols to initiate polymerization and alter polymer properties, and minimal steps are
usually necessary to develop the polymer. ROP also has the ability to develop high
molecular weight chains depending on the type of catalyst and molar ratios chosen for
synthesis, which control the number of monomeric units attached. These advantages
reveal the usefulness of ROP to create a unique polyprodrug as a biomaterial for drug
delivery.
The therapeutic prodrug simvastatin contains a 6-membered lactone ring that is
theoretically capable of being opened and reacted to form a polymer via ROP, much like
monomers of PLA and PGA. Simvastatin is well known as the active ingredient in
Zocor, an oral medication for treating hypercholesterolemia. However, the drug also
exhibits anti-atherosclerotic, anti-inflammatory, angiogenic, and osteogenic properties in
its active hydroxyacid form.120-123 Different polymeric devices have already explored
encapsulation and release of simvastatin for bone regenerative applications.79,
Simvastatin is readily metabolized, ensuring removal from the body.126

124, 125

Oral

administration of statins can cause adverse muscular and hepatic effects127 that likely are
related to the high frequency of large doses needed to overcome first-pass metabolism.
Polymerizing simvastatin addresses the issue of dose dumping, removes the need for a
bioinert polymeric carrier, and provides the option of increasing the loaded amount of
simvastatin while prolonging release at therapeutic concentrations.
The objective of the present studies was to investigate the polymerization of
simvastatin using ROP. Reactions were conducted at different temperatures to evaluate
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the effects of temperature via kinetic analysis. The copolymer was also subjected to
alkaline conditions to test degradation via hydrolysis.

3.2 Experimental
3.2.1 Materials
Simvastatin was purchased from Haouri Pharma-Chem (Edison, NJ).

Tin (II)

ethylhexanoate (stannous octoate), monomethyl ether poly(ethylene glycol) (mPEG),
anhydrous toluene, anhydrous diethyl ether, dichloromethane (DCM), and deuterated
chloroform

(CDCl3)

were

purchased

from

Sigma-Aldrich

(St.

Louis,

MO).

Tetrahydrofuran (THF) stabilized with 3,5-di-tert-butyl 4-hydroxytoluene (BHT) was
purchased from Fisher Scientific (Pittsburgh, PA).
3.2.2 Methods
3.2.2.1 Poly(ethylene glycol)-block-Poly(simvastatin) Synthesis. Approximately 400
mg microscale reactions of simvastatin (400 mg, 0.956 mmol) and mPEG (47.8 mg, 9.56
μmol) were performed to assess reaction kinetics using a procedure adapted from the
literature.128 All reactions were performed at 150 to 250 °C in a silica sand bath for
improved temperature control. Internal solution temperatures were found to be 10 to 20
ºC lower than the sand bath temperatures. The reactant components were dried at 130 °C
in a nitrogen atmosphere for 1 hr followed by the reaction temperature for an additional
hour. Samples for the initial time point were taken after the reactants melted into a
homogenous bulk mixture and before catalyst addition. After the drying period, 1 wt% of
stannous octoate dissolved in toluene was added to the melt by syringe. Each reaction
ran for 24 hr, with three samples taken at each of 0, 1, 4, 8, 12, 18, and 24 hr. The
theorized reaction scheme is shown in Figure 3.1a.
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A macroscale synthesis of the diblock copolymer (2.5 g) was performed at 230 °C
for 24 hr with the same reaction conditions described in the preceding paragraph. The
crude product was purified by vacuum filtration after obtaining the precipitate using
DCM as the solvent and cold diethyl ether in excess as the anti-solvent to further remove
any residual monomer. Simvastatin (0.4 g) with and without catalyst addition was heated
at 240 °C for 24 hr to assess the effect of temperature on its molecular weight.
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Figure 3.1 a) Tin alkoxide complex formation and proposed mechanism of ROP reaction
to form poly(ethylene glycol)-block-poly(simvastatin). b) Proposed mechanism of
hydrolytic degradation of the copolymer.
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3.2.2.2 Gel Permeation Chromatography (GPC). Molecular weight was measured
using a Shimadzu Prominence LC-20 AB HPLC system with a Waters 2410 refractive
index detector. Two 300 x 7.5 mm, 3 µm particle size ResiPore columns (Agilent
Technologies) in series were used for sample separation. Samples were injected using
THF as the eluent at a 1.0 ml/min flow rate. Standard curves were prepared using
polystyrene standards ranging from 160 Da to 370 kDa.

Shimadzu Lab Solutions

software was used to calculate weight- (Mw) and number-average molecular weight (Mn)
and the polydispersity index (PDI, Mw/Mn).

Simvastatin monomer conversion (i.e.,

molecular weight growth of the poly(simvastatin) block) was determined as a function of
time.
3.2.2.3 Nuclear Magnetic Resonance (NMR) Spectroscopy. H-NMR spectra were
developed from Varian Gemini NMR 400 MHz spectrometers connected to a VnmrJ
software interface. Samples of the copolymer and a melted mixture of simvastatin and
mPEG (100:1 molar ratio) weighing 5 to 7 mgs each were dissolved in 1ml of CDCl3,
transferred into NMR sample vials and analyzed for additional structure characterization.
3.2.2.4 Fourier Transform Infrared (FTIR) Spectroscopy. Spectra were obtained
using a Varian FTS-7000e FTIR spectrophotometer with a 0.25 cm-1 resolution. Samples
weighing 3 to 5 mg were placed directly onto a germanium attenuated total reflectance
crystal and compressed for analysis. The functional groups of the copolymer (synthesized
at 230 °C) were compared to those found in a melted mixture control of simvastatin and
mPEG, as well as the components individually. Peak locations and heights of stretches
characteristic of simvastatin and mPEG were identified in the copolymer and its control.
Comparisons of peak location and height were assessed.
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3.2.2.5 In Vitro Degradation. Small 16 to 18 mg disks were made by dissolving in
dichloromethane (60 wt%) and pipetting the polymer solution onto a Teflon plate to
evaporate the solvent overnight. Disks were placed in 3 ml of 1 M NaOH (aq) or
phosphate-buffered saline, pH 7.4 (PBS).

Disks were weighed and medium was

completely replaced at each time interval. Total dry weight of the disks was measured at
2 and 6 weeks. Aliquots were retrieved at intervals and analyzed for absorbance at 240
nm using a PowerWave HT Microplate Spectrophotometer with a Gen5 analysis software
interface. The theorized mechanism of degradation is shown in Figure 3.1b.
3.2.2.6 Matrix-Assisted Laser Desorption/Ionization – Time of Flight Mass
Spectrometry (MALDI–TOF MS).

Degradation supernatants were analyzed for

product identification, relative abundance of different products, and molecular weight
distribution using a Bruker Ultraflextreme MALDI-TOFMS in positive ion mode. This
instrument provides a smartbeam-II solid state laserbeam (355 nm) focus as low as 10
µm for quality spatial resolution, speed of up to 2 kHz, and a detector with a resolving
power and mass accuracy of 40, 000 and 1 ppm, respectively. Samples of simvastatin,
mPEG, and degraded products in PBS were lyophilized and then solubilized in THF. The
sample solutions were then centrifuged at 2500 rpm for 3 min to remove the undissolved
salts. The remaining supernatants containing the dissolved compounds were syringe
filtered (0.45 µm) before analysis.

Approximately 1 µL of each sample solution was

analyzed on a stainless steel target. Alpha-cyano-4-hydroxycinnamic acid (CHCA) was
used as the matrix.
3.2.2.7 Statistical Analysis.

Two-way ANOVA with a Bonferroni post-test was

performed on the kinetic data to test the effects of reaction time and temperature on the
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molecular weight growth of the copolymer and the effects of degradation time and pH on
simvastatin release from the copolymer. An unpaired student t-test was conducted to test
for differences between means of mass lost. Values of p<0.05 were deemed statistically
significant. Data were plotted as mean and standard deviation.

3.3 Results
Synthesizing poly(ethylene glycol)-block-poly(simvastatin) at 150 ºC and above
generated crude copolymers that increased in Mw with time (Figure 3.2). At 150 ºC, a
minimal Mw of 9.5 kDa was observed, which correlated to approximately two simvastatin
monomers in each chain. However, as the temperature of reaction increased above 200
ºC, polymer growth increased significantly, reaching poly(simvastatin) chain lengths of
19 to approximately 260 monomeric units attached to an mPEG block.

The latter

corresponded to a Mw of 74 kDa formed at 250 °C. The kinetics of the temperaturedependent reactions fitted best to a first-order rate model,
𝑀𝑊𝑡 = 𝑀𝑊𝑜 𝑒 −𝑘𝑡

(1)

where MWt is molecular weight at time t, MWo is initial molecular weight, and k is the
rate constant (Table 1). Reactions run at 150 and 200 °C showed significantly lower
rates of Mw growth, with constants of 0.0033 and 0.0169 hr-1 (Figure 3.2). First-order
kinetics became more evident as the temperatures of 215, 230, 240, and 250 °C led to
higher rate constants of 0.0052, 0.0042, 0.0782, and 0.0806 hr-1, respectively. Regardless
of the molecular weight values obtained at each temperature, the Mn values for the crude
products did not exceed 13 kDa (Table 1).
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Figure 3.2. Mw of copolymer during ROP at increasing temperatures. Simvastatin and
mPEG (5 kDa) were mixed at a 100 to 1 molar ratio for each reaction. The 0 hr time
point represents the Mw of mPEG before poly(simvastatin) chain growth. The GPC
molecular weight of mPEG registered higher than its theoretical value due to differences
in chemistry between mPEG and the polystyrene standards used. Data are mean ±
standard deviation (n=3).
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Table 3.1 Summary of the highest MW obtained, derived rate equation, and percentage in
the crude product at each temperature at 24 hr.
Temperature
(°C)

Rate equation

150
200
215
230
240
250

𝑦 = 8.74𝑒 0.0033𝑡
𝑦 = 9.20𝑒 0.017𝑡
𝑦 = 8.88𝑒 0.052𝑡
𝑦 = 8.57𝑒 0.042𝑡
𝑦 = 9.40𝑒 0.078𝑡
𝑦 = 9.81𝑒 0.081𝑡

Rate
constant
(hr-1)
0.0033
0.017
0.052
0.042
0.078
0.081

Mw at 24
hr (kDa)

Mn at 24
hr (kDa)

9.5
13.6
31.6
23.5
53.2
74.6

9.1
10.7
13.1
12.2
11.1
10.9

% in
crude
product
8.5
38
64
60
69
75

Figure 3.3 shows a chromatogram depicting the conversion of monomers (i.e.,
simvastatin, represented by the peak at 22 min) to a larger M w product at 250 °C. A
marked decrease in the monomer peak area represented rapid consumption to form
intermediate simvastatin-conjugates (17.5 to 21 min). The formation of product with a
Mw higher than that of mPEG followed. The extended Mw growth of the copolymer was
represented by a slight leftward shift from the peak of mPEG (17 min) and a broadened
shoulder, beginning at 10 min, to the maximum peak height at 16.5 min.
The PDIs corresponding to the Mw kinetics are shown in Figure 3.4. At 150 °C,
where minimal molecular weight growth was seen, the PDI remained at 1.05 after 24 hr.
However, at 200 and 230 °C, the values increased up to 1.3 and 1.9, respectively. PDIs
reached 4.8 and 6.9 at the highest temperatures of 240 and 250 °C, respectively.
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Figure 3.3 GPC chromatogram showing monomer (simvastatin) attachment to the mPEG
block to form copolymer at 250 °C. Chromatograms were normalized to the copolymer
peak. The 1 hr mPEG and simvastatin peaks are excluded from normalization due to the
monomer peak registering at a high intensity (6.4).
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Figure 3.4 Changes in PDI at different temperatures of 24 hr ROP reactions. The PDI at
0 hr represents solely the mPEG block, and the subsequent points reflect addition of
simvastatin monomers. Data are mean ± standard deviation (n=3).
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Further characterization of copolymer purification is shown by a GPC analysis of
the crude product and the resulting retentate (desired copolymer) and filtrate (lower
molecular weight products) (Figure 3.5). The copolymer peak after separation was seen
at an elution time of 16.5 min.

Intermediate products and unreacted simvastatin,

represented by the elution time range of 18 to 22 min in Figure 3.3, were removed from
the crude copolymer by subsequent vacuum filtration.

The vacuum filtration step

isolated the purified copolymer product in the retentate.
Analyzing the rate of propagation and the process by which the simvastatin
monomer converted to copolymer at high temperatures led to heating the monomer, with
and without the catalyst, at 240 °C to assess effects in the absence of mPEG as the
initiator. Interestingly, heating simvastatin alone and simvastatin with catalyst produced
molecular weights of 10±4.7 kDa and 14±11kDa with PDIs of 2.3±1.5 and 4.7±2.5,
respectively. Both products still had lower Mw values than the product obtained in the
high temperature copolymer reaction at 240 °C, which was 53 kDa with a PDI of 4.8.
The majority of the conjugation produced was represented by the intermediate
simvastatin product peaks, shown in Figure 3.3, most of which did not appear after
purification (Figure 3.5, Table 3.2).
NMR spectra of the monomer and copolymer synthesized at 230 ˚C are shown in
Figure 3.6. Integration measurements showed approximately 38 simvastatin monomers
attached within the poly(simvastatin) block in the sample. Simvastatin has a molecular
weight value of 418.57 Da, which led to a calculated Mw of 21 kDa, similar to the Mw
seen in the kinetics analysis at 230 ˚C.
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Figure 3.5 GPC chromatogram of separated products after purification of the crude
copolymer.
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Table 3.2. Summary of product Mw distributions from purification, measured via GPC.
Sample
Crude
copolymer
Purified
copolymer
Separated low
Mw weight
product

Component

Mw (kDa)

highest Mw
intermediates
monomer
highest Mw
intermediates
monomer
intermediates
monomer

11.5
2.1
0.3
10.2
0.4
0.2a)
3.2
0.3

a)

Composition
(%)
28
48
24
87
6.2
6.8
66
34

Yield (%)
-

18
-

The GPC calibration curve has greater error for molecules with theoretical molecular
weight values below 0.5 kDa, which may explain why the value for simvastatin monomer
is not consistent in the table and why the value registers lower than the molecular weight
value of 418.57 Da.
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Figure 3.6 H-NMR spectra in CDCl3 (7.25 ppm) of: a) simvastatin and mPEG mixed at
a 100:1 molar ratio and b) poly(ethylene glycol)-block-poly(simvastatin).
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FTIR analysis of the functional groups of the synthesized copolymer is shown in
Figure 3.7. Comparing the copolymer spectrum to the spectra of simvastatin and a
mixture of simvastatin and mPEG revealed a carbonyl (–C=O) band shift from 1704 cm-1
to 1722 cm-1. An increase in the band intensity ratio of the –CH-CH– peak (2900-3000
cm-1) to –C=O band was seen in the copolymer spectrum compared to the control
mixture.

The copolymer spectrum also exhibited stretches characteristic of both

simvastatin and mPEG, with the carbonyl band at 1722 cm-1 and the methyl ether band of
mPEG at 1096 cm-1.129, 130
Mass loss and drug release of the disks in PBS and 1 M NaOH are shown in
Figure 3.8. Over the first two weeks, water uptake by the samples led to an average
maximum mass four and three times the initial mass for incubation in PBS and NaOH,
respectively. The dry weights decreased 11 and 14% in the PBS and NaOH, respectively,
during this time. At 6 weeks, the wet masses were 102 and 68% of the initial mass for
PBS and NaOH, respectively, and the dry masses were 13 and 21% lower. The dry mass
loss for the NaOH group had a larger mean decrease compared to samples in PBS, but the
difference was not significant. The cumulative drug amounts released were 108 and 266
µg in PBS and NaOH, respectively. After an initial burst of 59 µg in 24 hr, a zero-order
release rate was observed in NaOH with a constant of 7.4 µg∙hr-1 between 1 and 10 days.
A first-order release rate followed with a constant of 21 d-1 for the remainder of the
degradation period. In PBS, after an initial burst of 37 µg in 24 hr, only 2.5 µg was
released during the following 8 days. A zero-order release constant of 2.1 µg∙d-1 was
determined for the remainder of the degradation period. The amounts of simvastatin
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released in PBS and NaOH were significantly different at day 2 (p<0.05), day 3 (p<0.01),
day 4 (p<0.001), and days 5 to 44 (p<0.0001).
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Figure 3.7 FTIR spectra of: a) mPEG, b) simvastatin, c) simvastatin and mPEG blended
at the same molar ratio used for the reaction (100:1), and d) poly(ethylene glycol)-blockpoly(simvastatin).
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Figure 3.8 Degradation and drug release during incubation of samples in PBS or 1 M
NaOH. a) Wet mass loss, b) dry mass loss, and c) drug release. Data are mean ±
standard deviation.
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Figure 3.9 Mass spectra of a) simvastatin, b) mPEG (5 kDa), c) low molecular weight
degradation products, and d) high molecular weight degradation products.

Mass spectral data identifying different species of degradation products are shown
in Figure 3.9. The mass spectrum of simvastatin (Figure 3.9a) shows a peak of the
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highest abundance at 441 mass–to–charge ratio (m/z), simvastatin’s ion or the parent ion,
and another distinct peak at 702 m/z. The mPEG mass spectrum (Figure 3.9b) displayed
a pattern of a bell-shaped distribution of peaks with the highest relative abundance at
5207 m/z, which corresponds well with the theoretical molecular weight of the mPEG
used for synthesis.

Within the low molecular weight spectrum of the degradation

products released (Figure 3.9c), the 441 m/z peak is present along with a peak at 460 m/z
among a multitude of distinct peaks ranging from 490 to 1062 m/z to the right of the
parent ion and 385 to 430 m/z to the left. In the high molecular weight spectrum of
degradation products released, the highest relative ion abundance at 5312 m/z (Figure
3.9d) and a similar but rightward shift in the distribution of peaks compared to mPEG.
Although present, the abundance of the 441 and 460 m/z peaks were approximately 50,
35, 60, 50, and 35% of the ions represented at a m/z of 402, 430, 551, 920, and 5312,
respectively, the peaks of the highest relative abundance representing the degradation
products.

3.4 Discussion
3.4.1 Copolymer Characteristics
The molecular and therapeutic properties of simvastatin are desirable for
investigating the synthesis of a novel degradable poly(ethylene glycol)-blockpoly(simvastatin) copolymer for its potential use in drug delivery. Different derivatives
of poly(ethylene glycol), which include mPEG, have been used as initiators for the
synthesis of block copolymers due to their reactive hydroxyl end groups,
biocompatibility, and ability to increase the solubility of hydrophobic counterparts.131
Reacting simvastatin with mPEG via ROP can lead to a simple one-step synthesis of a
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polyprodrug with unique characteristics. The reaction takes advantage of simvastatin
being a prodrug, changing its closed-ring form into monomeric units of its active
hydroxyacid, the opened-ring form of simvastatin (Figure 3.1a). The ester bond initially
in the lactone ring of simvastatin would be embedded in the backbone of its polymer as a
result of opening the ring. Thus, polymer degradation and drug release would occur by
the hydrolysis of labile ester bonds, allowing the copolymer to degrade into biomolecules
of simvastatin hydroxyacid and mPEG (Figure 3.1b). These components are metabolized
in the liver and excreted by the kidneys, respectively.132

3.4.2 Polymerization Mechanism
Lactone-based molecules, such as glycolide, lactide, ε-caprolactone, and their
combinations, have been used as monomers for the synthesis of PLGA, PLA, and other
aliphatic polyesters.133-135 Like these molecules, simvastatin possesses a lactone moiety
capable of chemically opening and developing into a polymer block by the ROP
mechanism using stannous octoate, a well-known tin metal catalyst. Aluminum and
yttrium isopropoxide (metallic), porcine pancreatic and candida antartica lipases
(enzymatic), and various carboxylic acids and amines in the presence of an alcohol
(organic) have also been used as catalysts, which in turn dictate the ROP mechanism that
occurs.136 The mechanism of stannous octoate is pseudo-anionic coordination-insertion
ROP.136,

137

The metal catalyst first forms a complex with the hydroxyl group of the

initiator to form an alkoxide. The more reactive alkoxide begins chain propagation by
coordinating with the lactone ring of the monomer, followed by “insertion” of the ring
into the alkoxide’s metal-oxygen bond.136, 138 Throughout the process, the alkoxide acts
as a nucleophile by attacking the carbon of the ring’s carbonyl group, leading to cleavage
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of the acyl bond and extended chain formation with its end bonded to the alkoxide, which
is otherwise known as a living polymerization.138 A 5 kDa mPEG was used in the
synthesis of the present polymers so only one reactive hydroxyl group would be available
for propagation of the poly(simvastatin) chain, creating a diblock copolymer.

3.4.3 Kinetic Analysis
It was necessary for simvastatin to be in a fluid-like state to ensure homogeneous
mixing of all components. This state was possible only above 138 °C, the melting point
of simvastatin139, hence the high temperature range chosen for conducting melt
condensation reactions.
temperature reaction.

However, insignificant growth was seen for the lowest
The same results were also seen for preliminary reactions

attempted using tin (II) trifluoromethyl sulfonate, and lanthanum and aluminum
isoproproxide at 150 °C and lipase b candida antarctica at 80 °C in toluene (data not
shown). Unlike glycolide and lactide, in which the cyclic lactone is their main structure,
the lactone ring of simvastatin represents only a portion of the molecule. The other
aromatic moieties of simvastatin may interfere with opening the six-membered lactone
ring. Lactones of this size also have relatively lower ring strain than do smaller lactones,
but their strain is still favorable for polymerization.140 This characteristic contrasts with
the cyclohexane counterpart of the lactone ring of simvastatin that does not polymerize
due to the stable chair conformation it assumes without the ester group present.141 Thus,
minimal chain growth between 150 and 200 °C may be due to a combination of ring
strain and steric hindrance resulting from the bulky side groups attached to the targeted
lactone ring of simvastatin, contributing to a lower than necessary reactivity.
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Evidently, the simvastatin to mPEG molar ratios present in the 240 and 250 °C
reaction products exceeded the initial 1 to 100 molar ratio in the melt. This finding may
indicate low mPEG participation in the reaction and increased interactions between
neighboring simvastatin molecules due to the higher weight percentage of the molecule
within the bulk reaction mixture. In addition to mPEG having a hydroxyl group able to
serve as the active group for initiation, simvastatin also possesses a secondary hydroxyl
group attached to its lactone ring, which was unprotected during these reactions.
Secondary hydroxyl groups are less reactive than their primary counterparts.142
Regardless, this available hydroxyl may have allowed chain propagation among the
monomeric units to create extensively branched chains before interaction with mPEG to
create the diblock copolymer. Simvastatin would then be considered a bifunctional latent
AB2 monomer capable of both initiating ROP, via the hydroxyl group on its lactone ring,
and chain propagation through the opening of its lactone ring.143, 144 Mevalonolactone, a
molecule structurally similar to simvastatin, has been used as a monomer for synthesizing
branched copolymers.144 Bifunctionality of the monomer can lead to a dendrimeric
architecture of the copolymer, and in this case, it can lead to the synthesis of linear–
hyperbranched mPEG–block–poly(simvastatin) copolymer chains fully capable of
exceeding the initial 1 to 100 mPEG to simvastatin molar ratio, as more simvastatin
monomers are added to the branched segments. Also, because simvastatin would be able
to compete with mPEG in initiating ROP and is in much greater abundance, more mPEG
would likely remain unreacted, which is represented by the low Mn in Table 1. The
neighboring monomer interactions and branching may explain why the profiles strayed
farther away from achieving a steady state as temperature increased within the given time
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period. Regardless, the propagation kinetics of the copolymer reaction exhibited firstorder rates, which is generally found to be the rate order of bulk ROP via insertioncoordination initiators.145 By comparing the temperature-dependent rate constants as a
function of temperature via the Arrhenius equation,
𝑘 = 𝑒 −𝐸𝑎⁄𝑅𝑇

(2)

where k is the rate constant, R is the universal gas constant, and T is absolute temperature,
an activation energy (Ea) of 14.5 kcal mole-1 was obtained.

The Ea found of the

copolymer reaction is slightly lower but comparable to the activation energy of L-lactide
undergoing ROP via insertion-coordination (19.6 kcal mole-1).146
The limited polymer growth below 200 °C indicates how propagation of the
simvastatin chain was a more kinetically-driven reaction. The occurrence of ring opening
and subsequent propagation depends on the size of the lactone ring, the bulkiness of side
groups attached to the ring, and the inclusion or lack of heteroatoms, all of which affect
ring conformation.138 High ring strain increases lactone reactivity and largely contributes
to the driving force for ROP. Thus, ROP may result from the loss of enthalpy (H) caused
by dissipated ring strain. Even with cyclic monomers of low ring strain, heteroatoms
present in the ring can increase the degrees of freedom of the resulting polymer, which
increases the entropy (S) of the reaction and drives the reaction towards completion.119
Also, depending on the reaction conditions used, such as the solvent and states of the
monomer and its polymer (i.e., liquid, gas, or amorphous or crystalline solid), the
monomer would be limited to: a) polymerizing above a floor temperature (+ΔH and ΔS);
b) polymerizing below a ceiling temperature (-ΔH and ΔS); c) polymerizing at any
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temperature (-ΔH, +ΔS); or d) not polymerizing at all (+ΔH, -ΔS).147 The Mw growth
data show an evident floor temperature with polymerization possible above 150 °C under
the given the melt condensation conditions. A more obvious indication of the reaction
having a floor temperature relates to the high melting point of simvastatin and physical
state necessary for the reaction to proceed. Without solvent present in the reaction vessel,
polymerization was limited to temperatures above 138 °C.

3.4.4 Polydispersity
Linear polymers made via ROP of lactone rings with low ring strain often have
broader molecular weight distributions than those made from lactone rings with high
strain, a major factor necessary for opening the ring and progressing the formation of a
polymer chain.138

High PDIs may result from reactions such as transesterification,

backbiting, or depolymerization. These occurrences can be represented by PDIs up to a
value of 2 by the Flory-Shultz distribution function.147 Even higher PDI values may
represent nonlinear forms of polymerization (i.e., branching). In the present studies,
reactions above 200 °C produced higher PDIs, possibly from poly(simvastatin) branching
considering that there was low mPEG participation in the reaction.

An increased

occurrence of side reactions likely contributed to a portion of the synthesized crude
copolymer due to substantially increased kinetic rates at high temperatures. Although
stannous octoate is an efficient catalyst, it is also known to promote transesterification148,
which would only be exacerbated at higher temperatures. Uncontrolled side reactions
would in turn contribute to higher PDI values.
The PDIs measured represent solely the copolymer peaks. The baseline did not
completely return back to its original intensity after the elution of the copolymer peak,
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indicating that there was still a residual amount of intermediates and unreacted
simvastatin remaining in the purified product sample. Further removal would require an
additional purification step in the procedure.

3.4.5 NMR Analysis
The chemical shifts labeled ‘g’ and ‘h’ in the copolymer spectrum represent the
mPEG block,149 while the remaining labeled shifts relate to the poly(simvastatin) block.
The broadened peaks that represent simvastatin up-field between 2.91 and 0.067 ppm
indicate polymerization that has occurred to form the poly(simvastatin) block. However,
the integration ratio of the poly(simvastatin) area upfield (2.91 to .067) to the area
downfield (7.22 to 6.71, ratio; 17.0) is far from 1, suggesting some sort of degradation or
other form of conjugation that may have occurred due to the high temperature of the
reaction. The residual side products as a result may explain the shifts seen beyond 6.71
ppm or it may be an artifact of the environment of copolymer’s proposed branched
structure.

3.4.6 Functional Groups and Bond Formation
The carbonyl shift shown in the IR spectrum of the copolymer suggested new
ester bond formation.

The change in height of the –CH-CH– stretch may be a

representation of monomer addition (with a –C=O group) to the mPEG block (without a
–C=O group).

Also, the copolymer spectrum showing peaks characteristic of both

components indicated that a chemical bond between the two blocks occurred compared to
the mixed control, which showed only peaks characteristic of simvastatin, regardless of
the presence of mPEG.
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3.4.7 Degradation
The samples in PBS showed an increasing trend in percentage wet mass in the last
3 weeks compared to those in NaOH. An increase in surface area due to disk breakage,
despite a minimal loss in dry mass, may have aided in an increased absorbance of
medium. The high water absorbance seen in both groups can also be explained by the
presence of the hydrophilic mPEG block of the copolymer.

The initial burst and

subsequent zero-order release observed may indicate small molecules of free simvastatin
and oligosimvastatin close to the sample surface being easily dispersed into the medium
with the aid of water absorption by mPEG. The first-order rate seen in the NaOH group
may be influenced by the existing concentration of simvastatin in medium or by the
scission process in which poly(simvastatin) breaks down into simvastatin, which is only
then detectable in solution. Even though 108 to 266 µg of simvastatin were released
from the samples during a 6 week period, release of other degradation byproducts, some
of which do not have maximum absorption at 240 nm, would account for the remaining
mass loss measured.
Degradation of the copolymer is expected to occur by the hydrolysis of labile
ester bonds in the polymer chains. In alkaline solutions, simvastatin is also known to
hydrolyze into its active open-ring form, simvastatin α-hydroxyacid.150 The simvastatin
hydroxyacid may be included in the components resulting from breakdown, along with
byproducts that may include oligosimvastatin chains, mPEG, and mPEG with minimal
monomers of simvastatin attached.

The hypothesized byproducts are based on the

presence of ester bonds that would be present between the monomeric units and between
the block components. The degradation process and products of other polyesters, such as
57

PLGA, have been well-documented in identifying soluble oligomers that then degrade
into the final products of lactic and glycolic acid in abiotic conditions.151
The mass spectra of the low molecular weight degradation products showed m/z
values of 441 and 460, indicating the presence of simvastatin in its closed and open ring
forms, respectively. The m/z values for simvastatin and simvastatin hydroxyacid have
most likely been influenced by salt adducts in the analytes (i.e. Na+, K+, and H+) because
the ions are produced by cationization.152 Salt adducts can be produced from any salts
present within the sample, such as the PBS to which degradation products and
simvastatin and mPEG controls were exposed before prepping the samples for MS
analysis.

Despite desalting the final sample solutions, a small amount of the salts

remained present for detection but not nearly enough to inhibit the generation of a clear
and readable spectrum.

However, salt detection can still contribute to decreased

ionization efficiency, which possibly influenced the increased baseline noise seen in the
low molecular weight region, along with low concentration.
A parent ion value of 441 m/z is likely the result of an attachment of Na+ (22 m/z)
to the parent ion (419 m/z). A simvastatin hydroxyacid ion would gain a molar mass
value of 18 due to hydrolysis, leading to an m/z value of 460, seen in the spectrum, if the
salt adduct is the same as the one on the parent ion and the H+ ion also attached. The
lower value peaks may represent a combination of fragmented ions of simvastatin, 153 the
CHCA matrix (189 m/z), and salt adducts present in the sample. The same indication
holds true for the peaks ranging from 490 to 693 m/z and the peak at 702 m/z in
simvastatin’s spectrum, along with the incorporation of ion clusters produced from the
matrix154 (i.e., molecule (M): 2M+Na+ and 2M+H+; 379 and 401 m/z, respectively) and
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the parent ion. The peaks of 920 and 1062 may incorporate dimer ions of simvastatin
along with the other combinations previously mentioned.
The pattern of peaks seen in the mPEG mass spectrum represents the repeating –
CH2CH2O– unit of the polymer. The rightward shift in peak distribution seen in the high
molecular weight degradation products indicates simvastatin monomers remaining
attached to the mPEG block. Salt adducts and the presence of complex ions can lead to
less defined peaks otherwise seen as a rise in the baseline under the peaks of the high
molecular weight products. Thus, the mass spectral data suggests that the supernatants
collected from the degrading copolymer contained a broad distribution of degradation
products, including simvastatin, simvastatin hydroxyacid, dimerized simvastatin, mPEG,
and mPEG with simvastatin monomers attached, some of which are possibly branched.
Despite the possibility of a branched architecture being known to accelerate
degradation rates because of an increased number of end-groups present per polymer
chain63 and the large amount of water uptake of the samples within a 6 week period,
limited degradation and slow simvastatin release rates were still seen within neutral and
alkaline environments. This effect was attributed to the slow cleavage rate of bonded
simvastatin monomers being the limiting factor and/or possible side reactions during
polymerization leading to less labile bonds. Thus, investigating methods to improve the
synthesis procedure to better control the ROP reaction would be beneficial in minimizing
the side reaction byproducts produced in the crude copolymer.

3.5 Conclusions
A degradable poly(ethylene glycol)-block-poly(simvastatin) copolymer can be
useful as a polymeric drug delivery system. The poly(simvastatin) block formed at and
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above 200 °C, showing potential for increasing the weight percentage of the prodrug in
the biomaterial. ROP of simvastatin reveals a new approach for polymerizing prodrugs
in the statin family and possibly in other classes of lactone-containing prodrugs that may
have less steric hindrance. Less bulkiness could provide better chain propagation at more
ambient reaction conditions. The minimal synthesis steps of ROP needed to polymerize
prodrugs, such as simvastatin, can be desirable in scaled-up production. Although Mw
increased with temperature and initial degradation was observed, the rate of bond
cleavage between simvastatin monomers and possible byproducts from side reactions
hindered mass loss and subsequent drug release. Despite slow degradation, release of
open and closed-ring simvastatin as well as simvastatin in poly(oligo)meric forms was
demonstrated. By minimizing the side reactions, degradability of the mPEGpoly(simvastatin) diblock copolymer could be improved, potentially providing sufficient
concentrations of simvastatin for extended treatment periods.
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Ch. 4 Tuning Properties of Poly(ethylene glycol)-blockpoly(simvastatin) Copolymers Synthesized via
Triazabicyclodecene
This chapter was reproduced from a manuscript accepted for publication, “Asafo-Adjei
T.A., T.D. Dziubla, D.A. Puleo, Tuning Properties of Poly(ethylene glycol)-blockpoly(simvastatin) Copolymers Synthesized via Triazabicyclodecene, (2017), Reactive
and Functional Polymers.”
4.1 Introduction
A wide range of catalysts with different mechanisms of action have been used to
synthesize degradable polyesters for biomedical applications. Common catalysts that
mediate ring-opening polymerization (ROP) of lactone-incorporated monomers include
tin (II) ethyl-hexanoate (stannous octoate) and other organotin compounds.29 Aluminum, lanthanum-, and zinc-based alkoxides have also been used in the synthesis of high
molecular weight (MW) poly(lactic acid) (PLA), poly(lactic-co-glycolic acid), and
poly(ε-caprolactone). 29, 31, 155
Stannous octoate and other metal and alkaline earth catalysts are known to be
efficient

148

, while enzymatic, acidic, and organic catalysts have reportedly shown lower

reactivity, producing low MW polymers.29,

156

Catalyst reactivity, however, can be

altered by modifying reaction conditions, the type or size of lactone monomer
incorporated into the feed, or functional groups of these catalysts. For example, changing
the diamine bridge of aluminum salen complexes from ethylene to dimethylpropylene led
to significantly increased polymerization rates of small

L-lactide,

ε-caprolactone, ε-

decalactone, and β-butyrolactone monomers, while low reactivities with ωpentadecalactone and other macrolactones were not significantly affected.157 Also, ROP
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reactions with diazabicycloundecene and N-methylated triazabicyclodecene (TBD)
organocatalysts generated polylactide MWs of 18 and 21 kDa, respectively, in the
presence of pyrenebutanol in chloroform under optimized conditions.
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The type of

catalyst used under specific reaction conditions can affect the degree of polymerization
and the resulting quality of the polymer synthesized.
In our previous studies, stannous octoate-mediated coordination-insertion ROP
was used to synthesize a newly developed poly(simvastatin)-poly(ethylene glycol)
diblock copolymer with potential anti-inflammatory, angiogenic, and osteogenic
properties following degradation.

While the catalyst was successful in mediating

poly(simvastatin) propagation with a methyl-terminated poly(ethylene glycol) (mPEG)
initiator, a narrow and high reaction temperature window served as a limitation that also
promoted undesirable transesterification reactions. After preliminary attempts with other
metal and organocatalysts, TBD was ultimately selected because of its efficient
performance at ambient temperatures,54 ability to work without a co-catalyst, metal-free
process, and accessibility.

TBD was also reported to rapidly catalyze synthesis of 26

kDa PLA, of which the MW could be modified by changing the molar ratio of initiator to
monomer in the feed.158
In the present study, the TBD-mediated poly(simvastatin) reaction was compared
with the stannous octoate-mediated reaction under similar conditions. Polymerization via
TBD was also evaluated with different MW mPEGs, catalyst percentages, and molar
ratios of simvastatin to mPEG. Hydrolytic degradation of the resulting poly(ethylene
glycol)-block-poly(simvastatin) (PSIM-mPEG) copolymers was also analyzed by
measuring mass loss and drug release.
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4.2 Experimental
4.2.1 Materials
Simvastatin

was

purchased

from

Haorui

Pharma-Chem

(Edison,

NJ).

Triazabicyclodecene, monomethyl ether poly(ethylene glycol) (mPEG), anhydrous
toluene, anhydrous diethyl ether, dichloromethane (DCM), and deuterated chloroform
(CDCl3) were obtained from Sigma-Aldrich (St. Louis, MO). Tetrahydrofuran (THF)
stabilized with 3,5-di-tert-butyl-4-hydroxytoluene (BHT) was procured from Fisher
Scientific (Pittsburgh, PA).
4.2.2 Methods
4.2.2.1

Synthesis

of

poly(ethylene

glycol)-block-poly(simvastatin).

Microscale

Microscale reactions of PSIM-mPEG using stannous octoate have been previously
described.159

Macroscale reactions (2 g) were conducted using simvastatin as the

monomer and mPEG (550, 2000, or 5000 Da) as the initiator. Molar ratios of 100:2 for
simvastatin to mPEG 550, and 100:1 for simvastatin to mPEG 2000 or 5000 Da were
used in the feed to synthesize PSIM-mPEG(550), PSIM-mPEG(2k), and PSIMmPEG(5k), respectively.

Simvastatin and mPEG were dried in a round bottom flask

embedded in a silica sand bath at 120 ºC for 1 hr under a continuous flow of nitrogen gas.
The internal bulk temperature was increased to 150 ºC for an additional hour before
adding 1 wt% of TBD to the homogeneous melt. Each reaction ran for 24 hr.
Microscale reactions (0.4 g) were also conducted for PSIM-mPEG(550)
copolymers with a TBD catalyst percentage of 0.1 or 1 wt%, a 100:1, 100:2 or 100:10
simvastatin to mPEG molar ratio, and crude samples taken at 0, 4, 12, 18, or 24 hr
reaction times.
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Polymer dissolved in DCM was slowly added to cold diethyl ether at a 1:7 v/v
ratio of DCM to ether and vacuum filtered to purify the crude PSIM-mPEG(5k) product,.
The purification process for PSIM copolymers with lower MW mPEG blocks involved
slowly adding cold diethyl ether to the polymer in DCM solution at a 1:20 v/v ratio,
followed by centrifugation and decantation of the supernatant.
4.2.2.2 Gel Permeation Chromatography (GPC). A Shimadzu Prominence LC-20 AB
HPLC system connected to a Waters 2410 refractive index detector was used to measure
the weight-average molecular weights of simvastatin, mPEG (550, 2000, and 5000 Da),
and the crude PSIM copolymers. Two Resipore columns in series (300 x 7.5 mm, 3 µm
particle size; Agilent Technologies) were used for separation. Samples were dissolved in
THF at 5 to 10 mg/ml. THF was also used as the mobile phase at a 1.0 ml/min flow rate.
Polystyrene standards were used to calculate MW ranged from 160 Da to 430 kDa.
4.2.2.3 Nuclear Magnetic Resonance (NMR) Spectroscopy.

H-NMR spectra were

obtained to characterize the PSIM-mPEG (5k) copolymer and a melted mixture of
simvastatin and mPEG at a 100:1 molar ratio using a 400 MHz Varian Gemini NMR
instrument connected to a VnmrJ software interface. Samples weighing 5 to 7 mg each
were dissolved in 1 ml of CDCl3, transferred into NMR tubes, and analyzed for additional
structural characterization. The number of simvastatin monomers present in the diblock
copolymer was calculated by integrating the area under the peaks representing
simvastatin relative to those associated with 5 kDa mPEG, of which the number of H
atoms in its structure was known.

With this ratio, the number of protons in the

poly(simvastatin) block of the copolymer was calculated and divided by the known
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number of protons in simvastatin to get the number of simvastatin monomers in the
diblock copolymer.
4.2.2.4 Matrix-Assisted Laser Desorption/Ionization – Time of Flight Mass
Spectrometry (MALDI–TOF MS). Degradation products of PSIM-mPEG(5k) were
analyzed using a positive ion mode Bruker Ultraflextreme MALDI-TOFMS.

The

procedure used for sample analysis was previously described.159
4.2.2.5 In Vitro Degradation. Films of each copolymer (10-15 mg) were made by
adding a small amount of DCM to polymer to create a viscous solution (700% w/v) that
was pipetted onto a Teflon sheet to dry overnight. Each film was gently shaken in 1.5 ml
of phosphate-buffered saline (PBS), pH 7.4, at 37 ºC. Supernatant was collected and the
medium completely replaced every 12 hr the first day, every other day the first week, and
at 2 to 5 d for the remainder of the 44 d degradation period. The remaining samples were
dried and weighed after 6 weeks to measure total mass loss.
4.2.2.6 High Performance Liquid Chromatography (HPLC). A Shimadzu Prominence
LC-20 AB HPLC system was used to analyze supernatants collected from the mass loss
study. One Luna C18 column (150 x 4.60 mm, 5 µm particle size) was used with an
isocratic mobile phase of acetonitrile and water with 0.1% trifluoroacetic acid (70:30
v/v). Absorbance was measured at 240 nm.
4.2.2.7 Statistical Analysis.

Two-way ANOVA with a Bonferroni post-test was

performed on the kinetic data to test effects of reaction time, catalyst percentage, and
molar ratio on MW, yield, and percent composition of the copolymer. The same analysis
was applied to the simvastatin amounts released during copolymer degradation. Values
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of p≤0.05 were deemed statistically significant. Data are plotted as mean and standard
deviation.
4.3 Results and Discussion
4.3.1 Polymerization Mechanism
The ROP mechanism governed by TBD is anionic.

From the literature, one

theorized mechanism suggests that the amidine imine nitrogen of the nucleophilic
catalyst attacks the carbonyl group on the lactone ring of simvastatin to form a temporary
intermediate as the acyl bond is broken. The secondary amine in the guanidine-based
organocatalyst attracts the alcohols within the reaction mixture (i.e., both on mPEG and
the propagating poly(simvastatin) block) via hydrogen bonding. This action propagates
the PSIM block of the PSIM-mPEG diblock copolymer.158 However, computational
analysis comparing the transitional state energies of proposed TBD-mediated ROP
reactions with L-lactide and methanol showed that the intermediate steps carried out via
hydrogen bonding had lower energy transitional states compared to nucleophilic
attraction throughout the reaction. The lower energy states due to hydrogen bonding
indicated a relatively more stable mechanism.160
In the proposed mechanism shown in Figure 4.1, the amidine imine nitrogen of
TBD attracts the hydrogen on the alcohol, in this case mPEG, to activate it. The activated
alcohol then attacks the carbon of the carbonyl group of the lactone ring of simvastatin.
The catalyst then changes orientation, subsequently hydrogen bonding to the oxygen in
the C–O bond in the lactone ring, while the secondary amine remains hydrogen bonded to
the oxygen in the carbonyl group. This transitional state initiates opening of the lactone
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ring. TBD is reformed after the hydrogen migrates away from the amidine imine to form
the hydroxyl end-group of the propagating polymer. 160

Figure 4.1. ROP mechanism using TBD catalyst via hydrogen bonding.
4.4.2 Stannous Octoate vs. TBD Catalyst Mediated Reactions
The mole percentages of simvastatin, intermediates, and copolymer throughout
the reaction using stannous octoate or TBD as a catalyst are displayed in Figure 4.2.
Within 24 hr, a decrease in simvastatin monomer was observed at a conversion rate of
0.052 hr-1 with 27.2% of simvastatin remaining when using TBD as a catalyst at 150 ˚C.
In contrast, stannous octoate did not lead to monomer conversion at this temperature. At
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200 and 230 ˚C, however, stannous octoate catalyzed rapid conversion, at 0.179 and
0.351 hr-1, respectively, 3 and 7 times the rate for TBD. Total monomer consumption
was reached at 12 and 8 hr for the stannous octoate mediated reactions at 200 and 230 ˚C,
respectively.

Figure 4.2 GPC measurements of the percentages of copolymer, intermediates, and
simvastatin monomer throughout the reactions in the crude products of a) PSIMmPEG(5k) synthesized via TBD at 150 ºC, b) PSIM-mPEG(5k) synthesized via stannous
at 150 ºC, c) PSIM-mPEG(5k) synthesized via stannous at 200 ºC, and d) PSIMmPEG(5k) synthesized via stannous at 230 ºC.
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The degree of polymerization achieved by an ROP reaction is greatly influenced
by the nature of the catalyst, cyclic monomer, or alcohol incorporated in the feed.
Stannous octoate has the necessary electrophilic qualities possessed by its metal cation
center, and it gains nucleophilic properties once formed into an alkoxide, becoming a
stereoselective catalyst in the mediation of ROP. The newly formed tin alkoxide is
subsequently attracted to the carbon of the lactone carbonyl group and cleaves the lactone
ring of the monomer at the acyl bond, propagating the polymer chain via a pseudoanionic coordination-insertion ROP mechanism. However, stannous octoate is a much
larger molecule than TBD with a MW of 405 Da, three times that of TBD at 139 Da
(Figure 4.3). After forming a complex with the alcohol, or 5 kDa mPEG, the resulting
metal alkoxide complex becomes even larger.

Figure 4.3 Structures of stannous octoate and TBD catalysts used in the ROP of PSIM.
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TBD is highly basic (pKa 26) and requires no cocatalyst, such as thiourea, in the
ring-opening of cyclic esters, compared to some of its monocyclic phosphazene, amidine,
and guanidine counterparts. The bicyclic structure of TBD also has two active nitrogen
centers that allow for electrophilic and nucleophilic bifunctionality, activating
simvastatin’s lactone ring and the hydroxyl group of the mPEG initiator, respectively, via
hydrogen bonding.161, 162 This bifunctionality removes a possible limiting step otherwise
necessary for stannous octoate to form an alkoxide in order to initiate polymerization.
These advantageous characteristics associated with the smaller and less sterically
hindered structure may give TBD relatively heightened sensitivity, selectivity, and ease
in mediating ROP with mPEG and simvastatin at a lower temperature.

These

characteristics may also explain why TBD was able to catalyze a ROP reaction of PSIM
at 150 ˚C, where stannous octoate was unsuccessful. TBD-mediated reactions were also
carried out at internal temperatures lower than 150 ºC (results not shown). Those
reactions, however, did not produce significant polymerization, showing that the window
for polymerization is still small, but still with a lower temperature threshold than would
be necessary for stannous octoate to polymerize simvastatin.
Monomer conversion increased with reaction temperature when catalyzed by
stannous octoate. Even after total monomer consumption, however, the polymer
composition in the crude product continued to increase as the relative percentage of
intermediates declined, suggesting an addition of intermediate products to the copolymer
structure after monomer consumption. This may be due to the secondary hydroxyl group
on the simvastatin lactone ring acting as another reactive site, potentially forming
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intermediates of dimers and small oligomers that are subsequently incorporated into the
copolymer.
4.3.3 NMR and mass spectrometry of PSIM-mPEG (5k) via TBD
H-NMR was performed to further support the MW of PSIM-mPEG(5k) measured
via GPC. As seen in the control of Figure 4.4a, the chemical shifts represented by r, s,
and t (4.21, 3.71, and 3.48 ppm) represent mPEG within the mixture. Simvastatin was
identified by the remaining chemical shifts within the spectrum. Seventeen simvastatin
monomers were calculated to be incorporated into the PSIM-mPEG(5k) copolymer
sample tested, leading to a MW of 12 kDa.
In the NMR control spectrum, the repeating ethylene oxide unit of mPEG is
represented by the chemical shift at 3.71 ppm, and the hydroxyl and methyl oxide groups
of the polymer block are represented by the 4.21 and 3.48 ppm chemical shifts,
respectively.

The disappearance of the 4.21 ppm chemical shift in the copolymer

spectrum reflects incorporation of the mPEG hydroxyl moiety into the copolymer
backbone after initiation. The absence or shift change of e and f, which represent the
lactone ring (Figure 4.4a) in the copolymer spectrum reflect a change in the lactone
structure or molecular environment as a result of ROP. The broadened peaks in Figure
4.4b indicate synthesis of a polymerized form of simvastatin. Broadening of the base of
the peaks was observed between 5.38 to 6.05 ppm, with letters a through d representing
more aromatic portions of the simvastatin monomers.
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Figure 4.4 H-NMR spectra of a) a 100:1 mixed control of simvastatin and mPEG and b)
the PSIM-mPEG(5k) copolymer synthesized via TBD. Figure 3a was reproduced from
Ref. 9 with permission from the Royal Society of Chemistry.
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Figure 4.5 displays the mass-to-charge ratio (m/z) spectra of PSIM-mPEG(5k)
degradation products. The inset in Figure 4.5a shows simvastatin represented by the
parent ion of 441 m/z.

The low MW degradation product spectrum (Figure 4.5a)

contained multiple peaks close to that of simvastatin at 404, 422, 439, 457, and 480 m/z,
but the intensities were low relative to the peak of highest abundance at 522 m/z. To the
right of the most abundant species, a multitude of smaller peaks was seen, ranging from
540 to 957 m/z.
In the mass spectra of low MW degradation products, the 404 m/z peak represents
fragmented simvastatin. The 422 to 480 m/z peaks, alongside the peak of highest relative
abundance at 522 m/z, reflect open or closed-ring simvastatin in the presence of a
combination of salt adducts remaining from the PBS (i.e., Na+, K+, and H+) used to carry
out polymer degradation. The alpha-cyano-4-hydroxycinnamic acid (CHCA) matrix (189
m/z) used in the analysis may also contribute to the m/z values. Peaks ranging from 540
to 957 m/z indicate the presence of simvastatin dimers and combined salt adducts or
matrix in the degradation products.
In the spectrum of the higher MW degradation products (Figure 4.5b), a wide
distribution was observed, with the highest relative abundance at 5561 m/z. The most
prevalent peak was slightly higher than the theoretical average MW of the 5 kDa mPEG
polymer used as an initiator in the synthesis of the PSIM-mPEG copolymer. The base of
peaks representing the higher MW degradation products was broadened compared to the
sharp and distinct peaks seen in the mPEG control (Figure 4b inset), indicating the varied
distribution of complex ions present in this m/z range, possibly representing mPEG and
mPEG with attached simvastatin monomer degradation products.
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Figure 4.5 Mass spectra of a) low MW PSIM-mPEG(5k) degradation products compared
to simvastatin control and b) high MW PSIM-mPEG(5k) degradation products compared
to mPEG control. Insets of controls in Figure 2a and 2b were reproduced from Ref. 9
with permission from the Royal Society of Chemistry.
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4.3.4 Poly(simvastatin) Copolymer Synthesis using Different mPEGs
Chromatograms of purified PSIM-mPEG copolymers initiated with 5k, 2k, or 550
Da mPEG and catalyzed via TBD are shown along with their respective reactants in
Figure 4.6. The resulting weight-average MW of PSIM-mPEG(5k), PSIM-mPEG(2k),
and PSIM-mPEG(550) copolymers synthesized were 15, 13, and 20 kDa, respectively,
with polydispersity indexes (PDIs) of 2.1, 2.2 and 2.5, respectively.

The mPEG

initiators with theoretical MWs of 5 and 2 kDa were measured to have slightly higher
MW values of 7.4 and 2.5 kDa via GPC, while the 550 Da mPEG and simvastatin
registered lower MW values of 0.4 and 0.2 kDa, respectively. ROP reactions with 5k
mPEG led to successful simvastatin polymerization when mediated by stannous octoate.
With 2k and 550 Da mPEG, however, polymerization reactions were not successful when
mediated by stannous octoate or other selected catalysts, such as lanthanum isopropoxide,
aluminum isopropoxide, tin triflate, lipase B from Candida antarctica, HCl∙EtO2,
potassium

methoxide

(KOMe),

1,3-dimesitylimidazol-2-ylidene

(IMes),

diazabicycloundecene (DBU) under varied reaction conditions (results not shown).
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and

Figure 4.6 GPC chromatograms of poly(simvastatin) synthesized via TBD using a)
5kDa, b) 2kDa, and c) 550 Da mPEG initiators compared with reactants.
TBD successfully catalyzed the synthesis of PSIM-mPEG copolymers using 5k,
2k, and 550 Da mPEG as initiators at 150 ˚C in melt conditions, possibly as a result of
high reactivity combined with less steric hindrance due to its small molecular size. The
poor performance of stannous octoate in the same conditions possibly indicated steric
hindrance between the catalyst and the simvastatin structure and hindered catalyst
stereoselectivity.
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4.3.5 Kinetics
Based on the copolymer and mPEG MWs measured via GPC, the PSIM
copolymer initiated with the lowest MW mPEG had the highest percentage of simvastatin
incorporated in the copolymer at 98%. PSIM-mPEG(2k) and PSIM-mPEG(5k) had 80
and 51% of drug incorporated, respectively. Percent yields of the three copolymers
exhibited an opposite trend, however, with the 550 Da mPEG-initiated copolymer having
the lowest yield, which increased as the MW of the mPEG block increased (Table 4.1).
This trend may be due in part to the decreased solubility of mPEG in ether as its MW
increases.
Table 4.1. GPC measurement of simvastatin and mPEG composition in copolymers
Copolymer

Molar
ratio

Percent of
sim in
copolymer

# of sim
monomers
per mPEG
initiator

Percent
yield

Percent of
mPEG in
copolymer

PSIMmPEG 5k

100:1

51

39

~17 to
30%

49

PSIMmPEG 2k
PSIMmPEG 550

100:1

80

52

~13%

20

100:2

98

96

~2%

2

The initial MWs measured for the three PSIM copolymers were significantly
different (p<0.0001) due to the MW differences of the mPEG initiators used for each
reaction (Figure 4.7a).

The MW of the PSIM-mPEG(5k) copolymer remained

significantly greater than for the other two copolymers throughout the reaction
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(p<0.0001).

PSIM-mPEG(2k) also had a significantly greater MW than PSIM-

mPEG(550) did after 12 and 18 hr (p<0.001) and 24 hr (p<0.0001).
The difference between the initial and highest weight-average MW reached
throughout the reaction, which correlates with the number of simvastatin monomers
attached, was greatest for the 550 Da mPEG initiator. This difference decreased as MW
of the mPEG initiator increased. The trend was further reflected by the rates of
polymerization throughout the 24 hr reaction period. Within the first 4 hr, the PSIMmPEG(550) reaction had the greatest change in MW, increasing by 5 kDa and plateauing
at approximately 6.1 kDa for the remainder of the reaction period. PSIM-mPEG(5k) had
the smallest change in MW growth in the first 4 hr, and the slowest first-order
polymerization rate of 0.021 h-1 for 18 hr before undergoing a MW decrease from 13.4 to
12.6 kDa. The PSIM-mPEG(2k) reaction showed a smaller 4 hr MW change and had a
lower polymerization rate than PSIM-mPEG(5k) did, but its rate was higher than for the
PSIM-mPEG(550) reaction. The total MW increase achieved was 6 kDa at a rate of
0.037 h-1. From initial MWs of 0.67, 3, and 9 kDa, copolymer MWs of 5.8, 9, and 13
kDa were achieved for PSIM–mPEG(550), PSIM-mPEG(2k), and PSIM-mPEG(5k),
respectively.
Although the differences in MW growth within the first 4 hr were not significant
in Figure 4.7b, there was a noticeably greater change observed for the reaction initiated
with a 100:10 ratio of simvastatin to 550 Da mPEG. Unexpectedly, reactions with the
smaller amounts of 550 Da mPEG (100:1 and 100:2 molar ratios of simvastatin to
mPEG) achieved lower MWs after 4 hr (p<0.0001 and p<0.001, respectively) compared
to the feed containing the most mPEG (100:10 sim to mPEG). The MW obtained from
78

the 100:1 molar ratio feed remained significantly lower than the others after 12
(p<0.001), 18, and 24 hr (p<0.0001).

The 100:2 molar ratio feed generated a

significantly lower MW than only the 100:10 feed after 4 hr (p<0.001).
The 100:1 and 100:10 sim to 550 Da mPEG molar ratios with the smallest amount
of catalyst resulted in the greatest MW growth (Figure 4.7c) when comparing the effects
of different molar ratios and weight percentages of TBD. MW growth was statistically
insignificant in the 100:10 melt with 0.2 wt% TBD during the first 4 hr. Despite the
initial lag, the polymerization rate during the first 12 hr was 0.221 hr-1, leading to an 8.3
kDa crude copolymer. In the last 12 hr, the rate decreased to 0.008 hr-1, resulting in a 9.1
kDa crude copolymer product formed. In the 100:1 melt with 0.2 wt% TBD, a 5.1 kDa
MW was formed during the first 4 hr, followed by a 0.026 h-1 rate for the remainder of
the reaction to yield a 9.9 kDa polymer. MW differences between the two ratios at 0.2
wt% were insignificant after 4 hr. Reactions with 1 wt% TBD were completed within 4
hr. Upon completion, however, MWs plateaued at lower values than their counterparts
did with 0.2 wt% TBD, which were 8.4 and 6.1 kDa for the 100:10 and 100:1 molar ratio
feeds, respectively. The final MWs were 8.5 and 5.8 kDa for the 100:10 and 100:1 molar
ratio feeds, respectively. The 100:2 melt with 1 wt% TBD reached a MW of 6.9 kDa
within the first 4 hr and had a first-order rate of 0.011 h-1 for the rest of the reaction
period, resulting in an 8.5 kDa crude product.
Due to the low yield of PSIM-mPEG(550), the amount of catalyst and molar
ratios of monomer to initiator were modified to improve yield and the degree of
polymerization. The kinetics of the PSIM-mPEG(2k) and PSIM-mPEG(5k) copolymers
were also monitored over a 24 hr period. The slower rate of polymerization as the MW
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of the mPEG initiator increased suggests that the larger mPEG molecules provided
greater steric hindrance.

The computational analysis of Chuma et al. showed that

alcohols with bulky, more sterically hindering side groups increase the potential for
destabilizing the transition state needed to initiate and continue polymerization.160
Although mPEG does not have bulky side groups, this reasoning could apply to the
mPEG size and resulting conformations it assumes in the melt.
The majority of MW growth of PSIM-mPEG(550) synthesized with 1 wt% TBD
was complete within 4 hr, which plateaued for the remainder of the 24 hr reaction period.
This may be explained by the rapidly reactive nature of TBD. At 0.1 mol%, TBD was
shown to fully polymerize lactic acid into PLA in 1 min.54 Also, a 6 d polymerization
reaction with cyclic trimethylene carbonate, carried out by MTBD, a guanidine
equivalent of TBD, was shown to be complete in a significantly shorter time of 15 min
when mediated by TBD.162, 163 TBD is known to be the most basic of its “superbase”
counterparts, resulting in polymerization rates that almost equal those catalyzed by Nheterocyclic carbenes, which can take seconds to complete a reaction. Future potential
avenues could investigate the kinetics of TBD-mediated PSIM copolymer reactions in a
shorter time period for more precise polymerization rates within the 4 hr period.
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Figure 4.7 MW growth kinetics for PSIM-mPEG copolymers synthesized with: a)
different mPEG MWs with 1 wt% TBD, b) different molar ratios of simvastatin to mPEG
(550 Da), and c) two different amounts of catalyst at two different molar ratios.

Opposing relationships between catalyst concentration and molecular weight of
various polymers have been presented in literature.156, 164, 165 One of these investigations
includes

the

analysis

of

trioxane

monomer

to

p-chlorophenyldiazonium

hexafluorophosphate catalyst molar ratios ranging from 5,000 to 20,000. At ratios up to
8,000, the resulting polymer molecular weight was inversely proportional to catalyst
concentration, reaching maximum MW values. As the catalyst concentration continued
to decrease with monomer to catalyst ratios between 8,000 and 20,000, the relationship to
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polymer molecular weight became directly proportional.164 A range of different initiator
concentrations tested with trioxane had no effect on the resulting poly(trioxane) MW in
melt conditions, but the same range explored in solution caused a decrease in MW as the
initiator concentration increased.165 The type of catalyst used can also influence the
relationship between catalyst concentration and MW.

Increasing concentrations of

catalysts such as sulfuric acid and titanium (IV) butylate were shown to mediate synthesis
of lower molecular weight poly(lactic acid) during polycondensation of L-lactide.156 A
similar inverse relationship was seen in the present studies where polymerization rates
and resulting MWs of PSIM-mPEG(550) reactions increased as the TBD catalyst weight
percentage decreased. This relationship may result from the chosen catalyst to reactant
ratios leading to reactions above or below a specific energy threshold, where the
relationship between simvastatin monomer and TBD catalyst is inversely proportional.
Mechanistically, increasing the catalyst content between 0.2 and 1 wt% may contribute to
an increase of chain transfer reactions mediated by the catalyst, where the hydroxyl
terminal end group of a propagating chain, activated by the TBD catalyst, may attack the
ester group within the backbone of another neighboring or growing chain. 166 This action
can lead to a decrease in MW of the polymer chain and, ultimately, a reduced weightaverage MW.
An increased monomer to initiator ratio typically results in greater MW because
fewer initiation sites are present, which leads to longer polymer chains at high monomer
conversion. An example of this occurrence is seen with the ROP of ε-caprolactone using
a calcium methoxide catalyst, which increased the resulting poly(ε-caprolactone) MW
from 5 to 11.4 kDa at 100% conversion as monomer/initiator ratio increased from 20 to
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100.167 While this trend was maintained in PSIM-mPEG(550) crude products with 0.2
wt% TBD, the resulting MW decreased as the initial simvastatin to 550 Da mPEG
initiator ratio increased using 1 wt% TBD. This unexpected latter observation may be
influenced by low monomer conversion in the crude product for the most hydrophobic
copolymer, which partially explains its low yield. Increasing the initiator present in the
melt (i.e., lowering the monomer to initiator ratio) provides more initiator sites for
potential polymer propagation. Even though this would lead to shorter chains or a lower
MW polymer at nearly 100% conversion, the crude products show monomer conversion
is still far from complete. At this stage, a larger number of chains present compared to
the remaining monomer in the crude may exert a greater influence on the overall average
MW increase seen in the crude products as the 550 Da mPEG initiator amount increased
in the feed.
Transesterification reactions and depolymerization with extended time may
explain the slight decreases in MW nearing the end of reaction for PSIM-mPEG(5k) and
PSIM-mPEG(550) with 1wt% TBD. TBD and similar organocatalysts show significantly
greater binding affinity to cyclic lactones than acyclic esters, which contributes to
transesterification reactions and may contribute to the low PDIs measured in the crude
products after 24 hr.162
4.3.6 Crude vs Purified Polymers
Figure 4.8 shows chromatograms of the PSIM-mPEG(550) copolymer before and
after purification via DCM/cold ether. The crude copolymer in the kinetic reactions
reached a maximum of MW of 6-7 kDa in contrast to the purified 19-20 kDa copolymer
noted earlier.

After precipitation, the purified product showed a peak that noticeably
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shifted left to an elution time of 15.1 min compared to the crude peak, which remained at
16.7 min. The measured weight-average MW of the polymer peak in the crude product
was 9 kDa, while the purified form was 21 kDa.

Figure 4.8 Chromatograms of PSIM-mPEG(550) before and after purification.
The significant difference in MW distribution between the crude PSIMmPEG(550) (approximately 6 kDa) and the purified copolymer (20 kDa) was due to the
large amount of low MW products remaining in the crude samples decreasing the weight
average MW. Also, the high MW purified product represented only approximately 2% of
the crude product. The PSIM copolymer yield increased as the MW of the mPEG
incorporated into the feed increased. Analysis of purified samples may have resulted in a
different MW trend between the copolymers, but the small amounts of crude product
collected from the microscales reactions (5 to 10 mg) made purification impractical.
For

macroscale

reactions,

investigating

new

solvent/anti-solvent

phase

precipitation systems may help to improve the yield of the PSIM-mPEG(550) copolymer.
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The increased hydrophobicity of the copolymer may be influencing its solubility in the
DCM/diethyl ether combination used for purifying PSIM-mPEG(5k) and PSIMmPEG(2k), thereby affecting its yield.

4.3.7 Degradation
A degradation study was conducted to compare mass loss and cumulative
amounts of simvastatin released from the PSIM copolymers (Figure 4.9). After 6 wk, an
average total mass loss of 28, 29, and 7% was observed, from which cumulative amounts
of 12, 5.2, and 0 μg of simvastatin were released from PSIM-mPEG(5k), PSIMmPEG(2k), and PSIM-mPEG(550), respectively. While mass loss for the 5 kDa and 2
kDa mPEG-initiated PSIM copolymers was similar, both exhibited significantly greater
mass loss compared to PSIM-mPEG(550), the most hydrophobic copolymer (p<0.05).
PSIM-mPEG(5k) and PSIM-mPEG(2k) each exhibited differing rates of simvastatin
release in later stages of degradation compared to the rates seen initially. From 12 hr up
to 10 days, 0.578 and 0.230 μg/d of simvastatin was released from PSIM-mPEG(5k) and
PSIM-mPEG(2k), respectively, which changed to slower rates of 0.124 and 0.052 μg/d,
respectively, for the remainder of the 44 d study. In the first 12 hr, a burst release of 1.6
and 1.1 μg was measured from the two copolymers, respectively. PSIM-mPEG(5k)
released a significantly greater amount of simvastatin than PSIM-mPEG(550) did during
the 44 d period (p<0.0001) and PSIM-mPEG(2k) on day 3 (p<0.001) and the remainder
of the study (p<0.0001). Simvastatin release from the PSIM-mPEG(550) copolymer was
negligible over the 44 d period. From observation, PSIM-mPEG(5k) experienced the
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most erosion, which began the earliest. PSIM-mPEG(550) remained the most intact with
breakage observed much later during the degradation period.

Figure 4.9 Degradation of PSIM-mPEG(5k, 2k, and 550) diblock copolymers showing a)
final mass remaining and b) resulting simvastatin release.
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Degradation of poly(simvastatin) is caused by cleavage of hydrolytically labile
ester bonds throughout the polymer chain, ultimately releasing molecules of simvastatin.
The degradation rate of poly(simvastatin) can potentially be tuned by modifying the
composition of the diblock copolymer.

While simvastatin, and subsequently its

respective polymerized form, is hydrophobic, mPEG is hydrophilic, giving the resulting
PSIM-mPEG copolymer an amphiphilic nature.

The higher the MW of mPEG

incorporated into the diblock copolymer, the more hydrophilic the resulting copolymer
becomes. Generally, the more hydrophilic the copolymer, the faster it should degrade in
a physiological environment. While PSIM-mPEG(2k) had a slightly higher average mass
loss than PSIM-mPEG(5k), this difference was insignificant.
The order of increasing mass loss during degradation of the PSIM copolymers
correlated with cumulative release of simvastatin. An increasing degradation rate with
increasing hydrophilicity was more evident when comparing the amount of simvastatin
released.

PSIM-mPEG(5k) released 2.3 times more simvastatin than did the less

hydrophilic PSIM-mPEG(2k) copolymer, with both releasing significantly more than
PSIM-mPEG(550), which experienced insignificant degradation. Concentrations of 0.32.4 µg/ml, 0.07-0.8 µg/ml, and 0-0.01 µg/ml were reached for PSIM-mPEG(5k), PSIMmPEG(2k), and PSIM-mPEG(550), respectively. Concentrations from PSIM-mPEG(5k)
were within and above the range reported for simvastatin to have therapeutic effects in
vitro, while the range for PSIM-mPEG(2k) was at the bottom and slightly below this
window 168. Note, however, the small size (10-15 mg) of the samples; the total amount of
simvastatin release can be adjusted via the mass of copolymer used. The negligible
amount of simvastatin released from PSIM-mPEG(550), the most hydrophobic of the
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PSIM copolymers, during the 8 wk time period may be due to hydrophobic interactions
between the PSIM block within the copolymer matrix and potentially free simvastatin
trapped within the matrix. Both are extremely hydrophobic, which would lead to a
considerably slow rate of simvastatin release from the matrix into the aqueous medium,
as seen by similar drugs incorporated in hydrophobic block copolymer delivery systems.
169

A loss of other degradation products, such as mPEG, simvastatin oligomers, or mPEG

with limited simvastatin monomers attached, most likely contributed to the significantly
greater total mass loss than simvastatin released. Within a 44 d degradation period, the
PSIM-mPEG(5k) copolymer synthesized via TBD lost twice as much mass than did the
same copolymer synthesized via stannous octoate in a previous study.159 The comparison
may indicate a greater amount of side reactions leading to less degradable byproducts
formed in the stannous octoate mediated reaction as a result of being conducted at a
higher temperature of 230 ˚C.
4.4 Conclusions
Triazabicylodecene, a highly reactive organocatalyst, was able to mediate the
ROP of poly(simvastatin) diblock copolymer using different MW mPEGs at a lower
reaction temperature than the previously used stannous octoate catalyst. This provides
the advantage of modifying hydrophilicity or hydrophobicity of the biomaterial that, in
turn, alters degradation rate for therapeutic treatments of different timescales.

The

potential to polymerize simvastatin at a lower temperature also decreases the incidence of
side reactions that generate undesirable byproducts that interfere with degradation of the
polymeric biomaterial. Lower reaction or processing temperatures would also be more
energy- and cost-efficient at an industrial manufacturing scale. The resulting hydrophilic
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copolymer synthesized via TBD was capable of losing significantly more mass within the
same time period than the same copolymer synthesized via stannous octoate. Simvastatin
release was modified as a result of using different MW mPEG initiators for synthesis.
Synthesizing and developing a poly(simvastatin)-mPEG diblock copolymer with tunable
degradation properties is desirable for tissue therapeutic applications.
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Ch. 5 Tuning Degradation and Mechanical Properties of
Poly(ethylene glycol) – Poly(simvastatin)-based Diblock
copolymer blends
This chapter was reproduced from a manuscript in preparation, “Asafo-Adjei T.A., T.D.
Dziubla, D.A. Puleo, Tuning Degradation and Mechanical Properties of Poly(ethylene
glycol) – Poly(simvastatin)-based Diblock copolymer blends, (2017).”

5.1 Introduction
Polymeric biomaterials are frequently used for drug delivery applications due to
the ability to tune the time-scale of polymer degradation to that of therapeutic treatment.
By changing comonomer or monomer to initiator ratios, blending with other polymers,
conjugating hydrophilic or hydrophobic blocks to the polymer, or by modifying the endgroup, architecture, or molecular weight, one can substantially alter degradation rate.170174

Poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid) (PLA), and poly(ε-

caprolactone) (PCL) are biocompatible polyesters widely used as drug delivery vehicles
that benefit from their tunable characteristics.25,

175, 176

Examples of FDA-approved

products include Arestin®, Respiredal®, ConstaTM, Trelstar® Depot, and Sandostatin
LAR® Depot, which release minocycline, resperidone, triptorelin, pamoate, and
octreotide acetate for periodontal disease, psychosis, prostate cancer, and acromegaly,
respectively.177

These diverse PLGA microparticle system therapeutics aim to

circumvent the disadvantages of their oral administration, which include frequent dosage
due to insufficient bioavailability, burst drug release, and toxic effects.178 In addition,
aliphatic polyester carriers in drug delivery serve to protect drugs against premature
degradation, extending their half-life in the body to increase bioavailability of these drugs

90

as opposed to forms of oral administration. In addition, specific polyesters, such as PCL,
degrade extremely slow, providing low dose, yet sustained, drug release.
While polymers that degrade in weeks to months are desirable for bone healing
applications, the period of polymer degradation exhibited by polymers such as PCL may
extend beyond the necessary period of treatment, impeding rather than aiding the healing
process.179 Furthermore, the associated slow rate of drug release may be therapeutically
ineffective. As a result, copolymerization with poly(ethylene glycol) (PEG), a
hydrophilic macromolecule, has been investigated to accelerate the degradation rate of
hydrophobic and crystalline polyesters, such as PCL.180 PEG-PCL block copolymers
have been used as in situ gels, porous scaffolds, and in collagen/hydroxyapatite/hydrogel
composites for bone tissue regeneration.179,

181, 182

Past investigations have also

controlled degradation of relatively less hydrophobic and more amorphous PLA and
PLGA polymers by copolymerizing with PEG to use as composite scaffolds, micro- and
nanoparticle systems for tissue healing, anti-cancer and gene therapy, and other targeted
drug delivery applications.65,

183, 184

Blending polyesters into different polymers

potentially combines the desirable physical properties of the individual polymers. For
example, Tsuji et al. reported that blending a minimal amount of PCL with poly(D,Llactic acid) (PDLLA) significantly enhanced elongation before failure, as well as the
Young’s modulus of the blend, with the opposite effect seen when the same amount of
PDLLA was added to PCL.185
To further combat the disadvantages of high burst release and insufficient drug
release, advanced drug delivery systems include polymer chains consisting of repeating
monomeric units of the drug, such as aspirin, poly(morphine), poly(trolox ester), and
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curcumin polymers, providing sustained and pseudo-zero order release for select
systems.42,

186-188

These polydrugs include the previously reported synthesis of

polymerized simvastatin.159 Most well-known for regulating cholesterol, simvastatin also
has osteogenic, angiogenic and anti-inflammatory properties desirable for tissue
regeneration.120-122, 127
While the weight percentage of simvastatin in poly(ethylene glycol)-blockpoly(simvastatin) (PSIM) can be controlled by the drug to initiator ratio, the hydrophobic
nature of the poly(simvastatin) block results in slow polymer degradation even following
copolymerization with mPEG. Tailorable properties of the block would be more
advantageous for regenerative drug delivery applications. Thus, the objective of the
present studies was to investigate the effects of blending poly(ethylene glycol)-blockpoly(lactic acid) (PLA) copolymers on the degradation and structural properties of PSIM.

5.2 Experimental
5.2.1 Materials
Simvastatin and D,L-lactide were purchased from Haorui Pharma-Chem (Edison,
NJ) and Alfa Aesar, respectively. Monomethyl ether poly(ethylene glycol) (mPEG),
triazabicyclodecene (TBD), tin (II) ethyl-hexanoate (stannous octoate), carboxyl esterase
from porcine liver, anhydrous toluene, anhydrous diethyl ether, dichloromethane (DCM),
ethanol (EtOH) and an HMG-CoA Reductase kit were purchased from Sigma-Aldrich
(product CS1090; St. Louis, MO). Tetrahydrofuran (THF) stabilized with 3,5-di-tertbutyl-4-hydroxytoluene (BHT) and acetonitrile (ACN) were purchased from PharmcoAaper (Shelbyville, KY).
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5.2.2 Methods
5.2.2.1 Poly(ethylene glycol)-block-poly(simvastatin) synthesis via TBD. Macroscale
reactions (3 g) were conducted to synthesize copolymers using simvastatin as the
monomer and mPEG (550, 2000, or 5000 Da) as initiator at a molar ratio of 100 to 1.
Within a round bottom flask immersed in a silicone oil bath, simvastatin and mPEG were
dried at 130 ºC for 1 hr under a continuous flow of nitrogen gas. The temperature was
increased to 150 ºC for an additional hour before adding 1 wt% of TBD to the
homogeneous melt. Each reaction ran for 24 hr. The reaction procedure and mechanism
of copolymer polymerization via a metal catalyst, stannous octoate, has been previously
studied.159
5.2.2.2 Poly(ethylene glycol)-block-poly(lactic acid) Synthesis via Stannous Octoate.
Macroscale reactions were conducted (5g) using D,L-lactide and mPEG (550, 2000, or
5000 Da) at a molar ratio of 100:1 monomer to initiator. Components were mixed and
dried at 140 ºC for 1 hr under a continuous nitrogen gas purge. The temperature was
decreased to 120 ºC for an additional hour before 1 wt% of stannous octoate dissolved in
toluene was added to the melt. Each reaction ran for 6 h.189
5.2.2.3 Purification. Crude PSIM copolymers using 5000, 2000, or 550 Da mPEG
(PSIM-mPEG(5k), (2k), or (550)) and the PLA copolymers were purified by dissolving
the crude products in DCM and pipetting the polymer solution into excess cold diethyl
ether as the anti-solvent. The purified products were isolated via vacuum filtration.
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5.2.2.4 Gel Permeation Chromatography (GPC). A Shimadzu Prominence LC-20 AB
HPLC system with a waters 2410 refractive index detector was used to measure the MW
of the copolymers synthesized. Two 300 x 7.5 mm, 3 µm particle size ResiPore columns
(Agilent Technologies) in series were used for sample separation. Samples were injected
using THF as the eluent at a 1.0 ml/min flow rate. Standard curves were prepared using
polystyrene standards ranging from 162 Da to 483 kDa.
5.2.2.5 Film Formulation. Purified PLA-mPEG with block components of 5000, 2000,
or 550 Da mPEG (PLA-mPEG(5k), (2k) or (550)) and PSIM-mPEG(5k) were dissolved
in DCM at 700 μg/ml for a viscous solution. Each PLA-mPEG copolymer was blended
with PSIM-mPEG(5k) at 20 wt%, and labelled 80:20 PSIM(5k):PLA(5k), 80:20
PSIM(5k):PLA(2k), and 80:20 PSIM(5k):PLA(2k), respectively. The PSIM-mPEG(5k)
and PLA-mPEG(5k) block copolymers were also blended at a 60:40 weight ratio (60:40
PSIM(5k):PLA(5k)), respectively. The mixture was also dissolved in DCM at 70 wt%
and vortexed into a homogeneous mixture before droplets were pipetted onto a Teflon
sheet. Discs were dried overnight.
5.2.2.6 In vitro Degradation.

A destructive mass loss study was conducted with each

of the purified copolymers and blended copolymers. After recording initial mass, each
copolymer disk was gently shaken at 37 ºC in 1.5 ml of phosphate-buffered saline (PBS),
pH 7.4, for 60 d. Additionally, disks of the same polymer blends were shaken in 1.5 ml
of 0.1% porcine liver carboxyesterase190, 191 in PBS at 37 ºC for 60 d. At 0.5, 1, 3, 7, 14,
42, and 60 d, three film samples from each copolymer group were withdrawn and dried
overnight to determine mass loss. After the first day, where supernatant was collected
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every 12 hr, PBS was replaced every 2-3 days the first week, followed by every 3-5 days
for the remainder of the 60 d period.
5.2.2.7 High Performance Liquid Chromatography (HPLC).

Simvastatin

concentrations in release supernatants were measured using a Hitachi Primaide system
equipped with a Kinetix Luna C18 column (150 x 4.60 mm, 5 µm particle size;
Phenomenex). Acetonitrile and water with 0.1 wt% trifluoroacetic acid (70:30 v/v) was
used as the mobile phase, and UV absorbance was measured at 240 nm.
5.2.2.8 Mechanical Testing. A Teflon mold was used to form cylindrical samples with a
2:1 height to diameter ratio (5 by 2.5 mm). Samples were made from PSIM-mPEG(5k),
the PLA-mPEG copolymers, and the copolymer blends. Using a Bose Electroforce 3300
mechanical testing instrument, uniaxial compression tests were run at 0.05 mm/s until a
displacement of 2.5 mm was reached.192

Compressive strength and modulus were

calculated from the load-displacement data and physical dimensions of the samples.
When measuring compressive strength, more crystalline polymers were measured at
yield, which was also peak strength. For the semi-crystalline polymers, strength was
measured just above yield and before the plastic region of the load vs. deformation curve.
The modulus was determined from the slope of the initial linear elastic region of each
curve.
5.2.2.9 X-Ray Diffraction (XRD). Powder and film samples, 10 to 20 mg each, were
analyzed using a Siemens D500 Diffractometer to determine the relative of crystallinity
of the PSIM and PLA copolymers and their blends. A 2θ angle range of 10 to 50 ˚ was
used for measurement at a rate of 1˚/min. Diffraction was performed at 30 mA and 40
kV. A VisxDACO software interface was used to obtain and analyze data. Relative
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percentage crystallinity was calculated by measuring the total area of crystalline peaks to
the total area of both crystalline and amorphous peaks in the diffractogram.
5.2.2.10 Biochemical Activity of Degradation Products. The activity of PSIM and PLA
degradation products in supernatants was tested by evaluating inhibitory activity on 3hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase.

A commercially

available assay kit was used to monitor oxidation of NADPH, which is dependent on the
conversion of HMG CoA to mevalonate.193-195 The optical density of each reaction
sample was immediately read at 340 nm using a PowerWave HT microplate
spectrophotometer with a Gen5 analysis software interface.
5.2.2.11 Statistical Analysis. Two-way analysis of variance with a Tukey-Kramer posttest was performed to test the effects of the blending ratio on the degradation rate and
release of simvastatin from PSIM(5k).

One-way analysis of variance was used to

compare means of the mechanical properties and HMG CoA reductase activity. A value
of p ≤ 0.05 was deemed statistically significant. Data are presented as mean and standard
deviation.

5.3 Results
The starting MW of the PSIM-mPEG(5k), PLA-mPEG(5k), PLA-mPEG(2k), and
PLA-mPEG(550) copolymers and blends degraded in the mass loss study was 13, 20, 16,
and 19 kDa, respectively. Figure 5.1 displays the mass loss and subsequent release of
simvastatin from the copolymer and blended films. Within the first 24 hr, significant
mass loss was observed, with 25, 37, 21, 21, and 20% initial loss from PSIM-mPEG(5k),
60:40 PSIM(5k):PLA(5k), 80:20 PSIM(5k):PLA(5k), 80:20 PSIM(5k):PLA(2k), and
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80:20 PSIM(5k):PLA(2k), respectively. The PLA copolymers lost up to 22% within the
first 24 hr.
At 60 d, the PLA copolymer with the smallest mPEG size experienced the least
mass loss at 26%. The amount of mass lost increased with increasing MW of the mPEG
block incorporated into the PLA copolymer, with up to 94% lost from the PLAmPEG(5k) copolymer films. PSIM-mPEG(5k) and its blended films underwent mass
loss within this range. After the initial loss, the rate of mass loss for PSIM and its blends
was similar, with rates of 0.44, 0.54, 0.6, 0.73, and 0.46 μg/d from the first 24 hr to end
of the 60 d for PSIM-mPEG(5k), 60:40 PSIM(5k):PLA(5k), 80:20 PSIM(5k):PLA(5k),
80:20 PSIM(5k):PLA(2k), and 80:20 PSIM(5k):PLA(550), respectively. The blend with
the highest amount of PLA copolymer (60:40) and highest MW mPEG showed the
greatest mass loss of 75%. Blends with a smaller PLA copolymer content (80:20)
retained more mass than did the 60: 40 blend and continued a trend of decreasing mass
loss as the mPEG MW in the PLA copolymer decreased, from 63 to 45%. A total mass
loss of 50% from the PSIM copolymer was comparable to that of its blend with the PLA
copolymer having the lowest MW mPEG.
The largest amount of simvastatin, 15 μg after 60 d, was released from the 80:20
blend with the highest MW mPEG block (5kDa) incorporated into both of the individual
copolymers. The two remaining 80:20 blends and PSIM-mPEG(5k) exhibited similar
release profiles with an insignificant difference in total simvastatin released, ranging from
7.8 to 8.3 μg. The 60:40 blend released 6.2 μg, the smallest total amount of simvastatin.
Increasing zero-order release rates of 0.24, 0.28, 0.3, 0.33, and 0.72 μg/d were observed
during the first 10 d followed by lower zero-order rates of 0.078, 0.11, 0.093, 0.094, and
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0.168

a

μg/d

PSIM(5k):PLA(550),
respectively.

for

60:40

80:20

PSIM(5k):PLA(5k),

PSIM(5k):PLA(2k),

and

PSIM-mPEG(5k),
80:20

80:20

PSIM(5k):PLA(5k),

The 80:20 PSIM(5k):PLA(5k) blend released a greater amount of

simvastatin than PSIM-mPEG(5k) and 60:40 PSIM(5k):PLA(5k) did from 3 d (p<0.01)
to 5 d (p<0.0001) and the remaining 60 d period (p<0.0001), along with 80:20
PSIM(5k):PLA(2k) (p<0.001) and 80:20 PSIM(5k):PLA(550) (p<0.01) from 7 to 60 d
(p<0.0001). Simvastatin released from PSIM-mPEG(5k) and 80:20 PSIM(5k):PLA(550)
was greater than the amount released from 60:40 PSIM(5k):PLA(5k) from 49 to 60 d
(p<0.05).
Overall, approximately 62 wt% of simvastatin was polymerized into the diblock
copolymer. An 8 to 15 μg amount of the drug (0.06 to 0.2 % of the monomer) was
released during the 8 week period. Throughout degradation of PSIM-mPEG(5k) and the
60:40 blend, concentrations of 0.08 to 0.5 μg/ml were reached, while the 80:20 blend
releasing the largest drug amounts reached concentrations between 0.2 and 1.2 μg/ml.
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Figure 5.1 Degradation of PSIM and PLA copolymers and their blends in PBS, pH 7.4,
showing a) mass loss and b) drug release profiles.
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To evaluate the sensitivity of the synthesized polymers to enzymatic degradation, another
mass loss study was conducted using PBS supplemented with 0.1 mg/ml
carboxylesterase. Table 5.1 compares cumulative release of simvastatin with and without
enzyme after 2 months of degradation. While the average simvastatin amount released
was

lower

in

esterase

solution

for

80:20

PSIM(5k):PLA(5k)

and

80:20

PSIM(5k):PLA(550), no significant difference in release was seen comparing PBS and
esterase solution conditions with each copolymer or copolymer blend.

Table 5.1: Comparison of simvastatin released from PSIM and blends in PBS and PBS
containing 0.1 wt% esterase.
Cumulative
Sim
Released
(μg)

PSIM(5k)

PBS

8.01
±1.71

PBS with
0.1 wt%
esterase

13.3
±1.28

60:40
PSIM(5k):
PLA(5k)

80:20
PSIM(5k):
PLA(5k)

80:20
PSIM(5k):
PLA(2k)

80:20
PSIM(5k):
PLA(550)

6.24
±0.344

15.2
±0.733

7.82
±0.523

8.33
±1.40

8.14
±2.93

8.50
±3.49

8.98
±5.27

2.83
±0.933

Figure 5.2 shows images of samples used for mechanical testing.

Although

characteristically orange in color, the PSIM copolymer samples appear somewhat
transparent along with their PLA copolymer counterparts, as opposed to the blends of
PSIM with each of the PLA copolymers, which appear opaque. The PLA-mPEG(5k)
copolymer was the least translucent of the three PLA copolymers, followed by PLA-
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mPEG(550), and lastly PLA-mPEG(2k). The mPEG block polymers tested also had a
characteristic opaqueness, white in color at room temperature.

Figure 5.2. Cylindrical mechanical testing samples of PSIM copolymers and blends.
From left to right: mPEG (5kDa), mPEG (2kDa), PLA(5k), PLA(2k), PLA(550),
PSIM(5k), 80:20 PSIM(5k):PLA(5k), and 60:40 PSIM:PLA.
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Figure 5.3 Mechanical properties of PSIM and PLA copolymers and blended samples:
a) compressive strength and b) modulus. *p<0.05,**p<0.01, ***p<0.001, ****p<0.0001
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The average compressive modulus and strength of PSIM-mPEG(5k) were 44 and
4.5 MPa, respectively (Figure 5.3).

Blending PSIM with PLA copolymers noticeably

decreased the resulting compressive modulus and strength to ranges of 26-36 MPa and
2.4-5.4 MPa, respectively. In contrast, no significant difference in modulus and strength
was seen between PSIM-mPEG(5k) and its blends. Also, there was no significant
difference in modulus between the blends and the respective PLA copolymers used for
each type, with the exception of 60:40 PSIM(5K):PLA(5K), which exhibited a
significantly lower modulus than did PLA-mPEG(5k).
Significant differences in compressive strength were seen between the blends and
the respective PLA copolymers incorporated in each blend type.

The compressive

strength of 2 kDa and 5 kDa mPEG was significantly lower than that of PSIMmPEG(5K). There was a noticable decrease in compressive modulus and large decrease
in strength (p<0.0001) as the mPEG block length in the PLA copolymer shortened from 5
to 2 kDa. However, the PLA copolymer with the shortest mPEG length (550 Da)
exhibited a higher modulus (although with high variability) and strength (p<0.0001) than
did PLA-mPEG(2k), which had a similar modulus but significantly lower strength
(p<0.01) compared to PLA(5k).
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Figure 5.4 X-ray diffractograms of mPEG block components, simvastatin and D,L-lactide
monomer components, PLA-mPEG copolymers, the PSIM-mPEG(5k) copolymer, and
PSIM:PLA blends.
Figure 5.4 displays the comparative crystalline and amorphous peaks between the
mPEG, PLA and PSIM polymers and blends, and their respective monomers obtained via
X-ray diffraction. The 5 kDa mPEG was normalized at 100% as the most crystalline in
the group when determining the relative crystalline index (CrI) between mPEG block
components and copolymers. The 2 kDa mPEG followed with 90%, and then PSIMmPEG(5k), PLA-mPEG(5k), 60:40 PSIM(5k):PLA(5k), and 80:20 PSIM(5k):PLA(5k)
with 16, 14, 12, and 7.8% relative crystallinity, respectively.

Similar amorphous

properties to the 5 kDa mPEG-containing blends were exhibited by 80:20
PSIM(5k):PLA(2k), 80:20 PSIM(5k):PLA(550), PLA(2k) and PLA(550) with 9, 11, 11,
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and 8.5% relative crystallinity, respectively. Distinctive peaks were observed at 20 and
24˚ (2θ) in the more crystalline polymers and blends.
The diffraction patterns of simvastatin and

D,L-lactide

also showed a semi-

crystalline nature of the monomers used in copolymerization, at 47.5 and 62.5%
crystallinity, respectively. Distinctive peaks of crystallinity characteristic to simvastatin
were seen at 11.1˚ and from 15 to 27 ˚ (2θ). The diffraction pattern characteristic to D,Llactide exhibited multiple crystalline peaks throughout the 2θ angle range of 11 to 43˚.

Figure 5.5. Inhibition of HMG-CoA reductase activity in the presence of simvastatin,
lactide, and PSIM and PLA degradation products at different concentrations. (n = 3)
*p<0.05, **p<0.01
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HMG CoA reductase activity was analyzed in the presence of PLA-mPEG(5k)
and PSIM-mPEG(5k) degradation products (Figure 5.5). Inhibition of enzyme activity
was seen with simvastatin at 0.01, 0.1, and 1 μg/ml concentrations and with PSIM
degradation products at the higher concentrations of 0.1 and 1 μg/ml. Compared to fresh
enzyme activity, the levels of enzyme inhibition were 39, 86, and 88% for simvastatin at
0.01, 0.1, and 1 μg/ml, respectively, and 58 and 68% for PSIM degradation products at
0.1 and 1 μg/ml, respectively,. The presence of lactide and PLA degradation products
exhibited minimal to no effect of enzyme inhibition at the concentrations analyzed.
While multiple noticeable differences in inhibition were observed, statistical significance
was seen for the PSIM degradation products at 0.1 and 1 μg/ml (p<0.05) compared to the
same products at 0.01 µg/ml, for which there was no noticeable enzyme inhibition. No
significant difference in inhibition was seen between the different simvastatin
concentrations, but the products of PSIM at 0.01 μg/ml exhibited significantly different
activity from simvastatin at 0.1 and 1 μg/ml (p<0.01). Simvastatin at 1 μg/ml also
significantly reduced reductase activity compared to D,L-lactide at 1 μg/ml (p<0.05).

D,L-

lactide and PLA degradation products did not show significant activity at any of the
concentrations tested.

5.4 Discussion
5.4.1 Degradation
The most influential factor affecting mass loss from the PSIM:PLA blends was
relative hydrophobicity between PSIM and PLA copolymers within the blends. This
factor, in turn, determined the rate of ester bond hydrolysis within the polymer backbone
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and degree of erosion that occurred. Simvastatin is hydrophobic due to the aromatic
rings found within its structure, a characteristic that increases in degree as simvastatin is
polymerized into its respective polymeric block. Lactide, a lactone molecule that lacks
aromatic moieties in its structure, is comparatively less hydrophobic, resulting in the
synthesis of a less hydrophobic polymer. Differences in mass loss between the blends
can be explained by relative hydrophobicity when evaluating the differences between the
PLA-mPEG diblock copolymers incorporated in the blends. Increasing the mPEG block
MW from 550 to 5000 Da created copolymers that decreased in hydrophobicity. This
trend led to an increased degradation rate as the association of water with oxygen-rich
mPEG, and subsequent access of water into the polymer matrix, increased with block
length.
The degree of compatibility between the PSIM-mPEG(5k) and PLA copolymers
in the blends and loss of residual mPEG and simvastatin reactants were possible
contributing factors to the significant initial erosion of the blends observed during the
first 24 hr. The initial mass loss from blends that had 20 and 40% of PLA-mPEG(5k)
may indicate phase separation between the two copolymers that was only exacerbated
upon increasing the weight percentage of PLA and/or leaching of PLA oligomers from
the bulk samples. The amount of PLA lost would not account for the total loss during
this period, however, as a detectable amount of simvastatin and intermediate PSIMmPEG(5k) degradation products were also present in the release supernatant.

The

slightly larger mass loss from PSIM-mPEG(5k) compared 80:20 blends may result from
leaching of free mPEG and monomer from the polymer matrix.
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The PLA degradation products, residual mPEG and simvastatin reactants, and
PSIM-mPEG(5k) intermediary degradation products, such as simvastatin oligomers,
would account for the three orders of magnitude difference in mass lost and simvastatin
monomer released from the blends, because only simvastatin monomer is accounted for
in the release profiles. The 80:20 blend most likely released the largest amount of
simvastatin due to a potentially lower internal pH environment in the bulk relative to the
other blends and PSIM-mPEG(5k) as a result of the higher degradation rate of PLAmPEG(5k) within the blended matrix. This comparatively accelerated process would, in
turn, enhance degradation of PSIM-mPEG(5k), leading to greater cumulative release of
simvastatin.

In contrast, the 60:40 blend releasing the lowest amount of drug was

possibly linked with the blend prematurely breaking up resulting in the early loss of PLAmPEG(5k) from the blended matrix. Without the faster degrading polymer, pH of the
internal environment within the remaining PSIM-mPEG(5k) matrix may not have been
low enough to accelerate cleavage of labile ester bonds to ultimately free larger amounts
of simvastatin.

Blended polyester systems have shown an increase in polymer

degradation in the presence a secondary acid producing biodegradable polymer (such as
PLA) within the matrix.196 In contrast, effects of neutralization to reduce degradation
rate have also been seen following incorporation of basic products in the blends.168
Relatively better integrity observed in the remaining blends correlated with higher
amounts of simvastatin released.
The simvastatin concentration range generated from the least hydrophobic 80:20
blend was within the concentration range of 0.5 to 1.5 μM (i.e., 0.21 to 0.42 μg/ml)
deemed to have a therapeutic effect in vitro. Similar simvastatin concentrations were
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reported by Song et al. to induce significant alkaline phosphatase activity in bone marrow
stromal cells.197 Concentrations from PSIM-mPEG(5k) were also within this range.
Another study found that a slightly higher concentration range of 1 to 10 μM of
simvastatin also induced VEGF mRNA expression in osteoblastic cells, showing similar
therapeutic concentration windows for different effects promoted by simvastatin.198
During degradation of the PSIM copolymer and its blends, open and/or closedring simvastatin and mPEG and other intermediate products may be produced as a result
of the breakdown of hydrolytically unstable ester bonds. Potential degradation products
include mPEG with a few monomers of simvastatin attached and oligomers of
simvastatin in the absence of mPEG, leading to increasingly hydrophobic
macromolecules as the number of simvastatin monomers on the oligomeric chain
increases. Some arguments have been made that in vitro degradation studies of polymer
drug delivery systems do not accurately represent performance in the physiological
environment due to the lack of enzymatic components and other biological factors that
may accelerate degradation of biodegradable polymeric systems. Tracy et al. showed
that PLGA microspheres injected into Sprague-Dawley rats exhibited degradation rate
constants 1.7 to 2.6 times faster than their degradation in vitro in a HEPES and KCl
buffer. As a result, the microspheres lasted a shorter time in vivo, from 14 to 60 d
compared to ~35 to over 60 d in vitro.199 In the present studies, there were no significant
differences seen between the PSIM:PLA blends degraded in PBS with or without
carboxylesterase.

Porcine

liver

carboxylesterase

was

chosen

because

carboxylesterases are known to contribute to metabolizing simvastatin.200

hepatic

Decreased

affinity of porcine liver carboxylesterase for PSIM macromolecules, despite its ability to
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metabolize simvastatin, could possibly explain the insignificant differences between
groups. Different types of liver carboxyl esterases exist show similar activity, but they
differ in conformation,201 which may have better affinity for PSIM. Further analysis of
PSIM degradation with different liver carboxyl esterases would better determine if their
structures would in turn influence affinity for PSIM.

The aromatic side groups of

simvastatin, more prominent in its polymerized form, may further inhibit access of the
enzyme to ester bonds compared to PLA and PLGA polyesters, which lack large side
groups. This potential concern of interfering side groups may be further exacerbated by
the random entanglement of polymer chains.
5.4.2 Mechanical and crystalline properties
While internal defects and voids within the samples played a part in their relative
opaqueness, inherent differences in their appearance may be due to possible differences
of indices between the two copolymers blended together. Refractive differences increase
light scattering between phases.202

For copolymers with similar, if not the same,

refractive index, light would transmit more easily creating the transparent appearance
seen in the PLA and PSIM copolymer samples. The opaqueness of the mPEG polymers
was due to their highly crystalline nature, much like the appearance of PCL, which is also
mostly crystalline at room temperature. Thus, PLA copolymers with the highest MW
mPEG appeared the least translucent of the three.
Mechanical properties of biodegradable copolymers play an influential role in the
balance of bone resorption and growth as the surrounding tissue heals. The average
compressive modulus and strength of trabecular bone in elderly adult human mandibles
are 56±29.6 and 4±2.7 MPa, respectively. For the cortical bone of elderly adult human
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mandibles, the compressive modulus was found to be higher at 96.2±40.6 MPa.203 The
mechanical properties of developed polymeric biomaterials for tissue regenerative
therapies are intended to mimic the properties of the surrounding bone to minimize
under- or over-compensation of loading put on bone, as described by Wolff’s law, which
would otherwise lead to decreased or increased bone turnover, respectively.204 However,
for the device to combat fatigue from damage and repeated loading, the argument of
developing implants with mechanical properties stronger than their surroundings has been
made because of their typically smaller cross-sectional areas than bone and lack of
reconstructive capability.205 In either case, being able to easily modify the mechanical
properties of biodegradable polymers via blending is advantageous.
The modulus and strength of PSIM-mPEG(5k) remaining within the same order
of magnitude of those for mandibular trabecular bone.203 Incorporating the same
percentages of each PLA copolymer in the blends (80:20) and also blending two different
amounts of PLA-mPEG(5k) (80:20 and 60:40) further decreased the modulus and
strength of the resulting blends (excluding the strength of 80:20 blend with PLAmPEG(2k)) compared to PSIM-mPEG(5k). The relative crystallinity of PSIM compared
to its respective blends correlated with the modulus comparisons between PSIMmPEG(5k) and the respective blends. This result may indicate a plasticizing effect of the
PLA copolymers incorporated,206

however the presence of small voids within the

blended sample matrix cannot be discounted as a contributor to the decreased properties.
Miscibility of the two polymers can also influence properties. While PEG is known to be
miscible with PLA, often referred to as a “compatibilizer” component of block
copolymers in polymeric blends, hydrophobic PCL has been shown to be immiscible
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with PLA.206 Low miscibility between hydrophobic PSIM and PLA block segments of
the copolymers could lead to boundaries between poorly or non-mixed regions within the
matrix, which could act as regions of stress concentration, thereby leading to lower
modulus and strength as the amount of PLA-mPEG(5k) increased. This effect could
explain the lower average strength of the 60:40 blend compared to its 80:20 counterpart.
The PLA copolymer samples had a modulus ranging from 26 to 97 MPa, resulting in the
PLA-mPEG(5k) and PLA-mPEG(550) samples measuring 1.7 times higher than the
values measured for trabecular bone.
The lower modulus and strength of the individual mPEG polymers compared to
the copolymers of PLA-mPEG(5k), PLA-mPEG(550), PSIM-mPEG(5k), and the blends
is due to the lower molecular weights of the mPEGs, despite their higher crystallinity
compared to the copolymers and blends. The properties of 550 Da mPEG were not
measured due to the liquid state of the polymer at ambient temperature.
The trends seen between the PLA copolymers may be due to competing effects of
plasticization and crystallization as a result of the length of incorporated mPEG blocks
and their influence on PLA block segments, relative PEG content of the copolymers, and
overall orientation of these block segments within various domains of the polymer
matrix. The weight percentage of PEG in PLA-mPEG(550), PLA-mPEG(2k), and PLAmPEG(5k) was 3, 13, and 25%, respectively. Kulinski et al. reported a plasticizing effect
of 600 Da PEG within the PLA domains as the PEG content increased from 5% to 12%,
resulting in decreased yield stress from 30 to 5 MPa.207 Plasticization may also explain
the decrease in modulus and strength of PLA-mPEG(2k) compared to PLA-mPEG(550).
The increased plasticization effect predominated the more crystalline nature of 2 kDa
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mPEG in PLA-mPEG(2k), compared to 550 Da mPEG in PLA(550), which would
otherwise potentially increase modulus and strength. Wu et al. showed that attachment
of a 5 kDa mPEG block impeded spherulite growth and thus chain folding ability of PLA
in the copolymer compared to PLLA homopolymers.208

Among the three PLA

copolymers synthesized, PLA-mPEG(5k) had the highest compressive modulus and
strength, which can be attributed to the higher crystallinity of the conjugated 5 kDa
mPEG block, compared to 2 kDa and 550 Da mPEG, combined with its high percentage
in the PLA(5k) copolymer. This effect may indicate that a critical ratio exists where
crystallinity of the high MW PEG begins to dominate over an otherwise plasticizing
effect.

While PEG hindered PLA chain folding, Wu et al. still calculated large 5 kDa

mPEG crystals even at low PEG ratios because of the ability of mPEG to crystallize.208
While PSIM-mPEG(5k) and PLA-mPEG(5k) exhibited similar crystallinity, the
higher modulus of PLA-mPEG(5k) may be the result of the higher MW compared to
PSIM-mPEG(5k). Stress concentrators from small defects within the samples may have
also played a role in the resulting compressive strength. Compared to the multiple distinct
peaks representative of the crystal lattice structure unique to simvastatin and the ordered
arrangement of mPEG crystallites in the 5 kDa mPEG polymer, the PSIM-mPEG(5k)
diffractogram has peaks similar to mPEG but a much lower relative intensity, in addition
to a noticeable halo underneath the two peaks.

The observed diffraction maxima

observed for PSIM-mPEG(5k) support the conjugation between the mPEG and PSIM
blocks and between the simvastatin monomers. The lower peak intensities may be
attributed to the PSIM-mPEG(5k) copolymer chains containing a lower mPEG

113

percentage compared to solely mPEG. The peaks and halo are representative of the
crystalline and amorphous regions of the PSIM(5k) copolymer, respectively.209

5.4.3 Bioactivity
Simvastatin is a well-known inhibitor of HMG-CoA reductase, a rate-limiting
enzyme in the cholesterol biosynthesis pathway. By inhibiting the enzyme, late-stage
prenylation of GTPase proteins (Rho, Ras, etc.) is affected, leading to the expression of
multiple properties. Apart from its role in lowering lipids, simvastatin has osteogenic,
anti-inflammatory, and angiogenic properties.120-123
A noticeable concentration-dependent inhibition of enzyme activity was observed
with both simvastatin and degradation products from the PSIM copolymer, reflecting the
known ability of simvastatin to act as a competitive substrate for HMG-CoA reductase.
In contrast, D,L-lactide and PLA degradation products did not show inhibitory activity.
As such, the

D,L-lactide

monomer and degradation products of PLA may serve as

controls in other future bioactivity studies. Lower activity of the PSIM degradation
products compared to simvastatin at the same concentrations was most likely due to the
components incorporated that do not have an effect on reductase activity, such as mPEG
or oligosimvastatin macromolecules that have not fully degraded into individual
molecules of simvastatin, which contributed to the total concentrations of the PSIM
degradation products.

5.5 Conclusions
Blending poly(simvastatin) with PLA provided an easier alternative to
copolymerization for enhancing and tuning degradation.
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Different mPEG sizes

conjugated to PLA and weight ratios chosen to blend PLA with PSIM copolymers led to
varied hydrophobicity, which consequently altered degradation and physical properties of
the

blends.

Incorporating

PLA

copolymers

at

different

ratios

plasticized

poly(simvastatin), reducing the compressive modulus, within a range comparable to that
of trabecular bone. The PSIM degradation products were also active in reductase
inhibition, a key factor for simvastatin exhibiting biological effects.
tailorable properties may be useful in tissue regenerative applications.
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PSIM and its

Ch. 6 In vitro and In vivo bioactivity of poly(simvastatin) –
poly(ethylene glycol) diblock copolymer for bone therapeutic
applications
This chapter was reproduced from a manuscript in preparation, “Asafo-Adjei T.A., T.D.
Dziubla, D.A. Puleo, In vitro and In vivo bioactivity of poly(simvastatin) – poly(ethylene
glycol) diblock copolymer for bone therapeutic applications, (2017).”

6.1 Introduction
Statins such as lovastatin (Mevacor) and simvastatin (Zocor) were approved by
the FDA in 1987 and 1988, respectively, as potent cholesterol-lowering agents.210,

211

However, these statins were later found to possess multiple properties making them
desirable for a range of therapeutic applications. Specific statins are preferred over others
for treatment depending on their relative potency at a given dose, relative lipophilicity,
bioavailability, and mechanism of metabolism, which may influence interactions with
other drugs and potential side effects experienced by patients.96, 210 However, simvastatin
was the most prescribed statin in 2010, the third most prescribed drug in the U.S., and it
continues to be the most investigated statin in the literature.210, 212, 213 Its popularity in
research is most likely due to the medium-potency and overall cost-effectiveness of the
prodrug compared to other statins.214 Structurally, simvastatin is the only statin aside
from lovastatin that resides in an inactive lactone form before it is introduced into a
physiological environment where it becomes active.210
When simvastatin is active in its open ring, hydroxyacid form, the molecule
competes with 3-hydroxy-3-methyl-glutaryl (HMG) as a substrate for HMG-CoA
reductase, inhibiting the rate-limiting and early step of the mevalonate pathway.
Isoprenoid precursors, such as geranyl-geranyl and farnesyl pyrophosphates (GGPP and
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FPP, respectively), which are indirectly inhibited further down the biosynthesis pathway,
inhibit the prenylation of Ras (via GGPP) and Rho (via FPP) proteins.215,

216

Rho

inhibition results in a significant increase in endothelial cell nitric oxide synthase (eNOS)
and subsequent nitric oxide (NO) production.216 NO and eNOS promote anti-oxidant and
anti-inflammatory activity through limiting platelet adhesion and promote cell survival
and blood vessel development through the PI3 kinase/Akt pathway and regulation of
vascular endothelial growth factors (VEGF).216,

217

Prenylation of T-cells is also

inhibited, leading to reduced macrophage activation and inflammation.218 Thus, the early
inhibition of cholesterol biosynthesis by statins affects other signaling pathways leading
to anti-atherosclerotic, angiogenic, anti-inflammatory, and anti-oxidant properties
necessary for tissue health and regeneration.120-123
The discovery by Mundy et al. in 1991 of the osteogenic nature of lovastatin and
simvastatin prompted a whole new avenue for using statins in biomedical applications.97
Simvastatin was observed to upregulate expression of BMP-2, which consequently
induced significant bone formation on the calvaria of ovariectomized mice. Upregulation
of BMP-2 by simvastatin has since been shown to be caused by the Ras/Smad/Erk/BMP2 signaling pathway.219 Reduction of mevalonate while BMP-2 is upregulated may also
be mediated by factors outside inhibition of the cholesterol biosynthesis pathway,
however.220 Mevalonate reduction has been shown to correlate with increased alkaline
phosphatase activity, an indicator of early osteoblast differentiation.221, 222 Additionally,
Rho inhibition suppresses osteoclast activity, allowing simvastatin to exhibit antiresorptive effects as well,223 although the anti-resorptive effects of statins are not nearly
as significant as osteogenic effects.97 While simvastatin, as with all treatments, proves to
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be ineffective below a therapeutic window unique to the drug, simvastatin at high doses
has promoted inflammation, myositis, rhabdomyolysis, and hepatotoxicity.99 To better
control statin loading and rate of release, a polymerized form of simvastatin was
previously synthesized via ring opening polymerization.159
The objective of the present studies was to compare in vitro bioactivity of PSIM
and PLA copolymer degradation products with, simvastatin, D,L-lactide, and BMP-2
control groups. A pilot study to evaluate polymer degradation and osteogenic activity in
vivo was also started.
6.2 Experimental
6.2.1 Materials
Simvastatin and D,L-lactide were purchased from Haorui Pharma-Chem (Edison, NJ) and
Alfa Aesar, respectively. Monomethyl ether poly(ethylene glycol) (mPEG),

and

triazabicyclodecene (TBD), β-glycerophosphate, ascorbic acid, thiazolyl blue tetrazolium
bromide, magnesium choride, 2-amino-2-methyl-1 propanol, sodium dodecyl sulfate,
dimethylformamide, and ethylenediaminetetraacetic acid (EDTA) were purchased from
Sigma Aldrich. BMP-2 was purchased from (Genscript), Dulbecco's Modified Eagle's
Medium was obtained from Corning, Fetal bovine serum (FBS) was obtained from
Atlanta Biologicals, and p-nitrophenyl phosphate was purchased from ---.
6.2.2 Methods
6.2.2.1 Copolymer synthesis. A macroscale reaction of PSIM-mPEG(5k) via TBD or
stannous octoate (3 g) was conducted using the synthesis procedures previously
described.159 Simvastatin was used as the monomer and mPEG with a weight-average
MW of 5000 Da at a 100 to 1 monomer to initiator molar ratio. A macroscale reaction of
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PLA(5k) using a procedure previously described in Section 5.2.2.2 was conducted (5g)
using

D,L-lactide

as the monomer and mPEG with a MW of 5000 Da at a 100 to 1

monomer to initiator molar ratio. The crude copolymers were purified by dissolving the
crude products in DCM and pipetting the polymer solution into excess cold diethyl ether,
as the anti-solvent. The purified products were isolated via vacuum filtration.
6.2.2.2 Degradation Products. PSIM(5k) and PLA(5k) were each degraded in 5 mL of
0.1 M NaOH (aq) for 30 d. Afterwards, supernatant with the degraded products from
each copolymer was collected and neutralized to pH 7.4 using 1 M HCl. Various
concentrations were made from the neutralized PSIM(5k) and PLA(5k) supernatants for
cell studies.
6.2.2.3 Cell culture. Murine myoblast C2C12 cells were obtained from American Type
Culture Collection (CRL-1772; ATCC, Manassas, VA). Cells were cultured in DMEM
with 10% fetal bovine serum (FBS), and incubated at 37 ºC in a 5% CO2 environment.
Culture medium was replaced every 3 days.
6.2.2.4 Cytotoxicity.

Cytotoxicity upon exposure to its degradation products was

assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay.224 MTT is reduced into formazan by dehydrogenase enzymes present in viable
cells. C2C12 cells were seeded at 20,000 cells/well in a 96-well plate and incubated
overnight.

Afterwards, 0.001, 0.01, 0.1, 1, and 10 μg/ml of PSIM-mPEG(5k)

degradation products, PLA-mPEG(5k) degradation products, simvastatin,

D,L-lactide,

and BMP-2 were added to the cells. PSIM-mPEG(5k) and PLA-mPEG(5k) were also
tested at at 100 μg/ml. After 24 hr, medium was replaced and 5 mg/ml of MTT in PBS
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was added to each well before incubating at 37 ºC for 2 h. Lysing buffer containing 20%
w/v sodium dodecyl sulfate in 50% dimethylformamide, pH 4.7, was added to each well
to solubilize the formazan produced by viable cells. The optical density of formazan was
read at a maximum absorbance wavelength of 570 nm using a PowerWave HT
microplate spectrophotometer with Gen5 analysis software.
6.2.2.5 Alkaline Phosphatase (AP) Activity.

C2C12 cells were seeded at 20,000

cells/well in 48-well plates for 24 hr, after which the culture medium was replaced with
αMEM containing 10% FBS, 5 mM β-glycerophosphate, and 50 µg/ml of ascorbic acid.
Cells were cultured for 4 days to reach confluence before treating with simvastatin, D,Llactide, PSIM-mPEG(5k) degradation products, PLA-mPEG(5k) degradation products,
simvastatin, BMP-2, or PBS. The same treatments with the addition of 20 µg/ml of
phenamil, active in BMP-2 upregulation, were run in parallel to assess the effects of the
compound. Medium with treatments were replaced every 3 days. After 3, 5, and 7 d,
buffer containing 50 mM sodium phosphate, 2 M sodium chloride and 2 mM EDTA was
added and followed by sonication to ensure cell lysis. Aliquots of lysate were mixed with
substrate solution containing 10 mM of p-nitrophenyl phosphate and 4 mM of MgCl2 in
0.6 M of 2-amino-2-methyl-1 propanol buffer, and the absorbance was measured at 400
nm as a function of time.
6.2.2.6 Myotube Staining. C2C12 cells with the same treatment groups were stained
with 0.01% of crystal violet for 30 min after fixation with methanol for 5 min. After
staining, the dye was aspirated and excess amounts were removed with 4 to 5 washes of
DI water. Cells were captured (10x) using an Olympus IX51 inverted microscope.
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6.2.2.7 Copolymer Disk Formulation.

Poly(simvastatin-block-mPEG) disks were

formulated by compressing the copolymer, in powder form, into a cylindrical dye with a
stainless steel rod under 8000 pounds of pressure for 5 min using a carver press. After
removing the samples from the dye, samples were annealed at 30 ºC for 24 hr and
subsequently at 60 ºC for 24 hr to form 4 x 6 mm disks (100 mg).
6.2.2.8 Pilot Animal Study. While in vivo analysis is ongoing and will not be completed
until late 2017 (Table 1), a trial study using a male Sprague-Dawley rat model was
conducted at the University of Kentucky in accordance with the Institutional Animal Care
and Use Committee protocol generated for biodegradable poly(simvastatin).

A

transverse incision was made between the ears and the periosteum was elevated before
placing a poly(simvastatin-block-mPEG) disk (4 x 6 mm, 100 mg) on the calvarium of
each animal. Poly(simvastatin-block-mPEG) disks were implanted to observe initial disk
behavior and the resulting tissue response up to 4 wk post-implantation. The calvarium
with samples still intact were fixated in phosphate buffered formalin for microCT
(Scanco Medical) to observe bone morphology at and surrounding the implantation site.
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Table 6.1 In vivo experimental design
Weeks after implantation
Treatments

1 wk

2 wks

3 wks

4 wks

6 wks

8 wks

6

6

6

6

6

6

Poly(simvastatin- 6

6

6

6

6

6

(50 mg disks)
Poly(simvastatin
-co-glycolide)
block-mPEG)
PLGA

6

6

6

6

6

6

PLGA with

6

6

6

6

6

6

encapsulated
simvastatin

6.2.2.9 Statistical Analysis. One-way ANOVA with a Tukey post-test was used to
analyze differences in cytotoxicity, and Two-way ANOVA with a Bonferroni post-test
was used for AP expression between treatments.

Mean and standard deviation are

plotted. A value of p ≤0.05 was deemed statistically significant.
6.3 Results
An MTT assay was conducted to determine the cytotoxicity for each treatment
group before selecting the concentrations to be used for AP expression in C2C12 cells.
In Figure 6.1, concentrations up to 100 µg/ml of PSIM and PLA degradation products,
and up to 10 µg/ml of simvastatin, D,L-lactide, and BMP-2 were cytocompatible with
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C2C12 cells after 24 hrs. The positive control of ethanol was the only group showing
significant cell cytotoxicity (p<0.001).

Figure 6.1 Cytocompatibility of simvastatin and lactide monomers and poly(simvastatin)
and poly(lactide) degradation products at different concentrations in C2C12 myoblast cell
cultures. Δp<0.001
Based on effective concentrations for the controls described in the literature and
cytocompatibility results, C2C12 cells were treated with 1 µg/ml of simvastatin, D,Llactide, or BMP-2 and 10 or 50 µg/ml of PSIM or PLA degradation products to measure
AP expression after 7d of confluency.
A 24 hr kinetic run of AP activity showed that activity began to plateau for one or
more groups after 2 hrs, so the 2 hr timepoint was used to compare groups with and
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without phenamil (Figure 6.2) at 3, 5, and 7 days post- confluency. In the absence of
phenamil, only simvastatin led to a difference in AP expression at 3d (p<0.01), followed
by both simvastatin and BMP-2 at 5 (p<0.01 and p<0.001, respectively) and 7d (p<0.001
and p<0.001, respectively). While there was a slight increase in AP activity with 50
µg/ml of PSIM(5k) degradation products, and 1.5 times higher than the PBS control, the
difference was not significant. BMP-2 promoted AP activity 1.5, 4, and 13 times higher
than the PBS control at 3, 5, and 7 d, respectively. Simvastatin promoted 2.5, 3, and 2.4
times more AP activity than PBS at 3, 5, and 7 d, respectively.
Simvastatin promoted greater AP expression with phenamil than without at 3 d
(p<0.001), followed by diminished expression at days 5 and 7 (p<0.05). BMP-2 was the
only treatment that resulted in increased AP activity at days 5 (p<0.001) and 7 d
(p<0.001), promoting higher AP expression compared to treatment without phenamil.
BMP-2 treatments with phenamil increased activity 1.6, 2.2, and 1.2 times more than
BMP-2 did in the absence of phenamil at 3, 5, and 7 d, respectively. Simvastatin with
phenamil increased AP activity 1.5 and 1.1 times more at 3 and 5 d, respectively,
followed by 0.16 times less activity at 7 d. PSIM(5k) degradation products at 50 µg/ml
led to only 1.1 times more AP activity at 5 d.
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Figure 6.2 Alkaline phosphatase expression by C2C12 myoblast cells in the presence of
poly(simvastatin) and poly(lactide) degradation products, simvastatin, D,L-lactide, BMP2, and untreated controls a) without and b) with phenamil. *p<0.05, #p<0.01, Δp<0.001
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Relative myotube thickness between the groups after 7 d is shown in Figure 6.3.
Cells treated with BMP-2 were excluded from the plot because the protein prevents
myotube formation, which is seen in Figure 6.3b. In the absence of phenamil, only
C2C12 myoblasts treated with simvastatin had significantly smaller myotube diameters
compared to the PBS control and remaining treatments (p<0.001), including D,L-lactide
(p<0.01).

Between the remaining groups, D,L-lactide treatment led to significantly

smaller myotubes formed than PLA(5k) did at 10 µg/ml (p<0.001), but it was not
different from the PBS control. A difference in myotube diameter was also seen between
PLA(5k) at 10 µg/ml having the thickest diameters and PSIM(5k) at 50 µg/ml and D,Llactide (p<0.01), but it was not significantly different from the PBS control.
When phenamil was present, the PBS control showed a difference in myotube
thickness compared to the other treatments (p<0.001).

Simvastatin with phenamil

resulted in even smaller myotube thickness compared to the remaining treatments
(p<0.001), including PLA(5k) at 50 µg/ml (p<0.01). Smaller myotube thickness from
PLA(5k) at 10 µg/ml compared to 50 µg/ml was seen as well (p<0.05).
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Figure 6.3 a) Relative myotube thickness normalized to PBS control at 7 d and b) cell
images comparing myotube formation between groups. BMP-2 was excluded from the
plot since myotubes did not form with treatment. n=10, *p<0.05, Δp<0.001.

Observations from up to 4 week trial runs of 4 x 6 mm poly(simvastatin) disks
implanted on the calvarium, beneath the periosteum, of Sprague-Dawley rats revealed
slightly varied findings in the physical and degradation behavior of the disks in vivo
(Figure 6.4). Within one week, observations ranged from an extensively fragmented
disk, to a relatively intact disk encased in a fibrous capsule at the implantation site, to
remnants of the disk remaining at the site. At the third week, similar disk conditions of
fragmented or intact disks were seen. The intact disks looked to have retained most if not
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all of their initial size up to wk 4, despite the disk conditions and the outlier of only
particles remaining in one of the animals at wk 1.

Figure 6.4 Images of fragmented and intact poly(simvastatin) disk samples at wk 1.
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Figure 6.5 a) Photographs of harvested calvaria with disks intact at 3 and 4 wks. b)
MicroCT images of calvaria of the same specimens.

The calvarium was harvested with the disk still encased in the fibrous capsule,
shown in Figure 6.5. MicroCT shows slight indentation where the implant was or an
otherwise different surface morphology compared to bone surrounding the implant,
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which will be investigated later, histologically. The observations seen in the pilot aided
in adjusting the disk dimensions for continuing with the main in vivo study giving insight
as to what to expect.

6.4 Discussion
Simvastatin has been shown to inhibit myoblast formation at 1 µM, and BMP-2 at
significantly lower concentrations,225 so the concentration chosen ensured a range where
AP activity and myoblast inhibition had been previously seen. C2C12 myoblasts are
normally known to differentiate into myotubes, which express characteristic biomarkers
indicative of muscle. With BMP-2 treatment, however, differentiation can shift to an
osteoblastic pathway in which cells express alkaline phosphatase, osteocalcin, and other
known biomarkers of osteoblastic phenotype. This pathway shift diminishes, if not
completely inhibits, formation of myotubes within the monolayer.226

While treating

C2C12 cells is not as relevant towards bone promoting applications as MC3T3-E1 preosteoblasts, the cell line was used instead to present a clearer distinction between the
positive control (BMP-2) and negative control (PBS) regarding AP expression.
Osteogenic biomarkers such as AP will not be expressed in C2C12 cells as they mature,
unless the treatment given promotes it, unlike MC3T3-E1 subclone 4 cells where AP
expression and osteoblast differentiation are inevitable and different forms of treatment
dictate the rate of that process.
BMP-2 is a potent stimulator of osteoblastic differentiation which is mediated by
a collective family of Smad proteins after BMP-2 binds to the type II receptor that
directly activates the type I receptor. Cyclin-dependent kinase 6 (cdk6) is subsequently
repressed via the Rho/Smad pathway, a protein that would otherwise play a key role in
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inhibiting osteoblastic differentiation.227 When added to C2C12 cells, the effects of
phenamil promoting the expression of osteogenic biomarkers are seen within a day ,228
and are more immediate compared to statins such as simvastatin that must first upregulate
BMP-2 in order to have the same effect. While myotube inhibition caused by BMP-2 has
been linked to the same Rho mechanism, simvastatin has been found to mediate myotube
inhibition via Rac by HMG-CoA reductase inhibition, different from the suppression of
Rho leading to BMP-2 upregulation which promotes AP expression in C2C12 cells.225
Regardless, the signaling pathways previously described explain how BMP-2 and
simvastatin are able to promote significant AP expression in both non-osteoblastic and
osteoblastic cell lines, which is why they worked well as positive controls.
Phenamil was chosen to supplement treatments due to its ability to augment the
osteogenic effects of BMP-2. Its upregulation of BMP-2 is done by stimulating tribbles
homolog 3 (Trb3), which enhances the BMP-Smad pathway.229 A concentration of 20
µM was used since one study found it as the highest to promote a dose-dependent.230 The
synergistic effect phenamil had with the active treatments of BMP-2 at 3, 5, and 7 d, and
simvastatin at 3 and 5 d can be attributed to the mediation of the BMP-Smad pathway.
The expression level is not cumulative as what would be seen with mineralization of an
osteogenic cell line, so the trend with decreasing AP activity up to 7 d post-confluency
seen with simvastatin is not unusual.. The expression levels of AP and other biomarkers
can change dependent on the differentiation stage of the cell line.

The small effect of

the PSIM(5k) degradation products without phenamil may be an indication of the amount
of simvastatin present compared to the other possible degradation products, i.e.,
mPEG(5k), dimerized or trimer simvastatin forms, and simvastatin attached to mPEG.
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Simvastatin is a very small percent of the products, with simvastatin release profiles from
the PSIM copolymer referenced in Chapter 4 showing amounts of simvastatin released
being 2 to 3 orders of magnitude lower than the total mass lost.

The simvastatin

oligomers may not be active and the rate of degradation into monomers if taken up by the
cells, remains to be determined. MPEG could also potentially hinder cellular uptake if
simvastatin is still attached contributing to minimized activity because of the size,
hydrophilicity, and uncharged nature of mPEG, rendering it difficult to being taken up by
cells.
Fragmentation of some disks when implanted over the calvarium may be due to a
mechanical stresses imposed on the sample. Possible reasons include initial disk
movement before formation of the fibrous capsule over the disk, the high activity and
grooming of the animals at or near the implantation site, and the slightly more brittle
nature of the disk.

The disk fragments may have also induced a large amount of

inflammation at the site, further exacerbating the condition of the disk. The outlier of a
majority of the disk being resorbed may be due to the residuals being found in the tissue
more above the intended site. The indentation seen in microCT may indicate possible
wearing of existing lamellar bone under the disk from minor but repeated disk movement
within the implantation site. The morphology may otherwise indicate possible formation
of new woven bone surrounding the disk as opposed to underneath, accentuating the
indentation observed. This observation was seen and quantified in an in vivo study
conducted by Jeon et al., where the thickness of bone underneath the intermittent and
sustained simvastatin releasing devices was significantly lower than the woven bone
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thickness surrounding it.231 The observation will be further investigated in the main
study with H&E staining.

6.5 Conclusions
Poly(simvastatin) degradation products were cytocompatible with myoblast cells
at concentration levels at and above therapeutic levels of simvastatin. However, they
promoted low to minimal osteogenic activity, which may be attributed to a significant
percentage of the degradation products still in a conjugated and inactive state.
Poly(simvastatin) disks in vivo were shown to affect the surface morphology of bone
under and at the periphery of the disks. Whether these changes are an indication of new
bone growth remains to be determined, but alongside its cytocompatibility, this
copolymer shows potential for use as a regenerative biomaterial with further
development.
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Ch. 7 Summary and Conclusions
Polymerizing a commercialized cholesterol-regulating prodrug known as
simvastatin via ROP was explored as a proof of concept. Degradation, simvastatin
release, physical properties, and bioactivity of the resulting polymer were evaluated for
potential use in bone regenerative applications.
By modifying reaction parameters, variation in reaction temperature was
ultimately found to have the most effect on increasing the degree of simvastatin
polymerization via stannous octoate. Further investigation of different catalysts led to
desirably lower reaction temperature conditions, via TBD.

Chromatography and

spectroscopy techniques used to corroborate simvastatin conjugation supported the
feasibility of utilizing the lactone ring of simvastatin to synthesize a diblock copolymer
backbone comprised of simvastatin monomers in the secondary block. This observation
opens a window to the ROP of many other lactone-incorporated drug precursors
implemented in a variety of therapeutic drug delivery treatments that would benefit from
an increased drug wt% while providing controlled release.
Using the TBD catalyst also allowed for the synthesis of PSIM copolymers
initiated by mPEGs of decreasing sizes, releasing more simvastatin with decreased
hydrophobicity.

Blending different hydrophobic PLA-mPEG copolymers with

poly(simvastatin) also resulted in modified rates of mass loss, simvastatin release and
modified mechanical properties.

These examples of copolymerization and blending

demonstrate methods to easily tune poly(simvastatin) degradation and mechanical
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properties, to better match different time periods of treatments. Lactide, glycolide, εcaprolactone, or ricinoleic acid lactones, their respective polymers, or different PEG
structures could be randomly or block copolymerized with simvastatin to further alter
degradation or mechanical properties of the resulting copolymers more suitable to
different delivery applications. Likewise, poly(simvastatin)-incorporated blends with
these alternative polyesters or composites utilizing hydroxyapatite or calcium-based
components could be considered to investigate the osteogenic nature of the resulting
biomaterial alongside its structural properties and conformity to abnormal shapes of
wound-sites in load-bearing bone.
Degradation products of PSIM inhibited HMG-CoA reductase potential
enhancement of osteogenic expression and biocompatibility in vitro and in vivo. These
observations demonstrate the potential to promote bone growth. Because HMG-CoA
inhibition is linked to the expression of simvastatin’s osteogenic properties, in addition to
angiogenic and anti-atherosclerotic properties, future investigations of degradable
poly(simvastatin) can potentially be broadened to include localized applications for
maintaining vascular health. The tailorable qualities provided by copolymerizing
pleiotropic simvastatin and co-blending its polymerized form can result in biomaterials
suitable for a broad range of therapeutic drug delivery applications from vascular to bone
regeneration.

Copyright © Theodora Atta Asafo-Adjei 2017
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